INVA


Line plots across dimensions of each concept
Line plots across concepts
Tables

Table of contents



us-gaap:CommonStockValue

us-gaap:CommonStockSharesIssued

us-gaap:PreferredStockSharesAuthorized

us-gaap:CommonStockSharesOutstanding
us-gaap:StatementEquityComponents

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareDiluted
us-gaap:IncomeStatementLocation
us-gaap:AllocatedShareBasedCompensationExpense

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

us-gaap:GainLossOnInvestments
us-gaap:ConsolidatedEntities
us-gaap:CounterpartyName

us-gaap:GeneralAndAdministrativeExpense

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

us-gaap:IncomeTaxExpenseBenefit

us-gaap:InterestExpense
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:InterestExpenseDebt

us-gaap:InterestPaidNet

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted

us-gaap:OperatingExpenses
us-gaap:ConsolidatedEntities

us-gaap:OperatingIncomeLoss
us-gaap:ConsolidatedEntities

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:ProfitLoss
us-gaap:ConsolidatedEntities
us-gaap:StatementEquityComponents

us-gaap:ResearchAndDevelopmentExpense

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ConsolidatedEntities
us-gaap:ConsolidatedEntities, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:ProductOrService
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement
us-gaap:RelatedPartyTransactionsByRelatedParty

us-gaap:Revenues

us-gaap:Assets
us-gaap:ConsolidatedEntities

us-gaap:LiabilitiesAndStockholdersEquity
us-gaap:ConsolidatedEntities

us-gaap:StockholdersEquity
us-gaap:ConsolidatedEntities

us-gaap:AssetsCurrent
us-gaap:ConsolidatedEntities

us-gaap:CashAndCashEquivalentsAtCarryingValue
us-gaap:ConsolidatedEntities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:PrepaidExpenseAndOtherAssetsCurrent
us-gaap:ConsolidatedEntities
us-gaap:ConsolidatedEntities
us-gaap:AssetsNoncurrent

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:LongTermInvestments
us-gaap:ConsolidatedEntities

us-gaap:DeferredTaxAssetsLiabilitiesNet

us-gaap:OtherAssetsNoncurrent
us-gaap:ConsolidatedEntities
us-gaap:EquitySecuritiesFvNi
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType
us-gaap:CounterpartyName, us-gaap:FinancialInstrument

us-gaap:AccountsPayableCurrent

us-gaap:LiabilitiesCurrent
us-gaap:ConsolidatedEntities

us-gaap:OtherLiabilitiesCurrent
us-gaap:ConsolidatedEntities
us-gaap:LiabilitiesNoncurrent
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:LongTermDebt

us-gaap:LongTermDebtNoncurrent

us-gaap:MinorityInterest

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
us-gaap:StatementGeographical

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
us-gaap:StatementGeographical

us-gaap:StockholdersEquity
us-gaap:ConsolidatedEntities

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents

us-gaap:CommonStockValue

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:MinorityInterest

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
us-gaap:StatementEquityComponents

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:AmortizationOfFinancingCosts

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DepreciationDepletionAndAmortization

us-gaap:IncreaseDecreaseInAccountsPayable

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:ProfitLoss
us-gaap:ConsolidatedEntities
us-gaap:StatementEquityComponents

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:EffectiveIncomeTaxRateContinuingOperations
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:DeferredTaxAssetsNet

us-gaap:UnrecognizedTaxBenefits

us-gaap:DeferredTaxAssetsValuationAllowance
us-gaap:ProductOrService, us-gaap:Range, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement
inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement
inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement
inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement
inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty
inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
us-gaap:ConsolidatedEntities
inva:IncreaseDecreaseInEquitySecuritiesAndLongTermInvestments

inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument
inva:PaymentsToAcquireEquitySecuritiesFvNi
us-gaap:ConsolidatedEntities, us-gaap:RelatedPartyTransactionsByRelatedParty
inva:PercentageOfAnnualPerformanceAllocationBasedOnNetProfits
us-gaap:ConsolidatedEntities
inva:PercentageOfEconomicInterestInPartnership
us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement
inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
dei:LegalEntity, us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument
inva:SecuritiesPurchaseAgreementAmount
us-gaap:ConsolidatedEntities, us-gaap:CounterpartyName, us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument, us-gaap:SubsequentEventType
us-gaap:CounterpartyName, us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:StatementScenario, us-gaap:FinancialInstrument, us-gaap:SubsequentEventType
inva:SecuritiesPurchaseAgreementPurchasePrice
us-gaap:ConsolidatedEntities
inva:VotingAgreementMaximumVotingRightsPercent
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:AmortizationOfDebtDiscountPremium

us-gaap:AmortizationOfFinancingCostsAndDiscounts
us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty
us-gaap:CapitalizedContractCostAmortization

us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
us-gaap:ConsolidatedEntities
us-gaap:EquitySecuritiesFvNiUnrealizedLoss
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

us-gaap:IncreaseDecreaseInAccruedLiabilities

us-gaap:IncreaseDecreaseInDeferredLeasingFees

us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent

us-gaap:IncreaseDecreaseInInterestPayableNet

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:InterestExpenseDebtExcludingAmortization

us-gaap:InterestOnConvertibleDebtNetOfTax
us-gaap:ConsolidatedEntities
us-gaap:InvestmentIncomeInvestmentExpense

us-gaap:InvestmentIncomeNet

us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium

us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

us-gaap:OtherNoncashIncomeExpense
us-gaap:ConsolidatedEntities
us-gaap:PaymentsOfStockIssuanceCosts
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation

us-gaap:PaymentsToAcquireLongtermInvestments

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:PaymentsToMinorityShareholders

us-gaap:ProceedsFromIssuanceOfCommonStock

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
us-gaap:Range, us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap:Range, us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
us-gaap:Range, us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
us-gaap:Range, us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap:StatementEquityComponents
us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
us-gaap:StatementEquityComponents

us-gaap:UnrealizedGainLossOnInvestments
us-gaap:ConsolidatedEntities

us-gaap:WeightedAverageNumberOfSharesIssuedBasic

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseAfterYearFive

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseNextTwelveMonths

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFive

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFour

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearThree

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearTwo
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
inva:ConvertibleSeniorDebtFairValueDisclosures
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
inva:ConvertibleSubordinatedDebtFairValueDisclosures
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

inva:EquitySecuritiesFvNiNonCurrent

inva:LongTermDebtMaturityAfterYearFour
us-gaap:IncomeTaxAuthority
inva:OperatingLossCarryforwardsIndefinitePeriod
us-gaap:RelatedPartyTransactionsByRelatedParty
inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty
us-gaap:ConsolidatedEntities, us-gaap:StatementScenario, us-gaap:FinancialInstrument, us-gaap:SubsequentEventType
inva:SecuritiesPurchaseAgreementNumberOfSharesPurchased
us-gaap:ConsolidatedEntities, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType
us-gaap:AssetsFairValueDisclosure
us-gaap:ConsolidatedEntities, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType
us-gaap:CounterpartyName, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType
us-gaap:CounterpartyName, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
us-gaap:CounterpartyName, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:CounterpartyName, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType
us-gaap:CounterpartyName, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
us-gaap:CounterpartyName, us-gaap:FinancialInstrument
us-gaap:CounterpartyName, us-gaap:InvestmentType
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
us-gaap:RelatedPartyTransactionsByRelatedParty
us-gaap:CapitalizedContractCostAccumulatedAmortization

us-gaap:CapitalizedContractCostNet
us-gaap:RelatedPartyTransactionsByRelatedParty
us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument
us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
us-gaap:CounterpartyName, us-gaap:FinancialInstrument

us-gaap:DebtInstrumentCarryingAmount
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:DebtInstrumentFairValue
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
us-gaap:DebtInstrument, us-gaap:LongtermDebtType

us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

us-gaap:DeferredIncomeTaxAssetsNet

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch

us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts

us-gaap:DeferredTaxLiabilitiesInvestments

us-gaap:DueFromRelatedPartiesCurrent
us-gaap:ConsolidatedEntities

us-gaap:EmployeeRelatedLiabilitiesCurrent

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
us-gaap:AwardType
us-gaap:ConsolidatedEntities
us-gaap:EquityMethodInvestmentOwnershipPercentage
us-gaap:CounterpartyName

us-gaap:InterestPayableCurrent

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
us-gaap:StatementGeographical

us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
us-gaap:ConsolidatedEntities
us-gaap:MembersEquity
us-gaap:IncomeTaxAuthority
us-gaap:OperatingLossCarryforwards
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
us-gaap:AwardType
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
us-gaap:IncomeTaxAuthority
us-gaap:TaxCreditCarryforwardAmount
us-gaap:IncomeTaxAuthority, us-gaap:TaxCreditCarryforward

us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Other Nonoperating Income Expense
Balance Sheet
Liabilities Current
Assets
Property Plant And Equipment Net
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Property Plant And Equipment Net
Liabilities
Liabilities Current
Current Liabilities
Accounts Payable Current
Noncurrent Liabilities
Other Liabilities Noncurrent
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInOperatingActivities
Increase Decrease In Prepaid Deferred Expense And Other Assets
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
Shares
Weighted Average Number Of Shares Outstanding Basic
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year

Tables

  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:CommonStockValue ▅▅▅█▁▁1.0141.0141.0141.0151.0131.013NANA1.0121.0111.0111.0151.0141.0191.08NA1.0931.085NA1.1161.1321.149NANANA1.1641.1541.1331.1251.1151.1051.008NA0.9840.9790.9690.8650.855NANANA
us-gaap:CommonStockSharesIssued █▇▇▇▃▁101.408101.392101.391101.392101.32101.288NANA101.183101.098101.189101.657101.475102.046108.152NA109.348108.585NA111.617113.146114.933117.575NANA116.445115.38NANA111.516NANANANANANANANANANANA
us-gaap:PreferredStockSharesAuthorized ▄▄▄▄▄▄0.230.230.230.230.230.23NANA0.230.230.230.230.230.230.23NA0.230.23NA0.230.230.230.23NANA0.23NANANA0.5NANANA0.23NANANA0.23NANANA
us-gaap:CommonStockSharesOutstanding █▇▇▇▃▁101.408101.392101.391101.392101.32101.288NANA101.183101.098NANANANANANANANANANANANANANANANANA113.285112.519111.516110.543100.766NA98.37997.85496.88286.4785.543NANANA
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding 113.624NA113.572113.545113.509NA113.415113.391113.376NA113.363113.399113.566NA119.796120.463120.336NA121.993124.316113.178NANA115.329114.658NANANANANA106.92597.603NANA95.02789.16992.08NA82.4981.81180.854
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic 101.365NA101.358101.324101.235NA101.191101.151101.059NA100.936100.873100.604NA106.841107.614107.487NA109.282111.359112.482NANA115.329114.658NANANANANA106.92597.603NANA95.02789.16983.59NA82.4981.81180.854
 us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities inva:EquityIncentivePlansAndESPP1.159NA1.2681.1541.094NA1.1441.1881.053NA1.5571.6331.492NA1.7792.0193.062NA3.8814.2763.917NANA7.1785.866NANANANANANANANANANANANANANANANA
us-gaap:EarningsPerShareBasic ▃▂▂▃▃▂▂▂▂█▂▂▂▂▁▂▁▂▁▁▁0.930.530.280.760.650.450.390.370.332.610.470.540.290.550.220.330.160.240.140.130.04NANA-0.07-0.09NANANANANA-0.44-0.37NANA-0.37-0.421.01NA-0.37-0.31-0.28
us-gaap:EarningsPerShareDiluted ▃▂▂▃▃▂▂▂▂█▂▂▂▂▂▂▁▂▁▁▁0.840.490.260.690.590.420.360.340.312.340.430.490.270.50.210.30.150.220.130.130.04NANA-0.07-0.09NANANANANA-0.44-0.37NANA-0.37-0.420.93NA-0.37-0.31-0.28
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
 Net profit Margin us-gaap:ConsolidatedEntities inva:TheravanceRespiratoryCompanyLlc22.084NANANA16.135NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 Operating Margin us-gaap:ConsolidatedEntities inva:TheravanceRespiratoryCompanyLlc22.084NANANA16.135NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
 TTM Greenblatt ROC _ _█████▇▇▇▆█▇▇▆▇▆▆▅▆▅▅▅▅▄▄▄▄▄▄▁▂▂▂▃▃▃▂█▂▃79.48384.78784.4375.79176.11573.63960.79359.7652.16877.2257.66162.67540.69566.40940.02247.8329.34338.01627.91825.87717.53217.2938.4345.1080.7450.13-9.542-9.794-66.244-48.452-45.238-41.786-33.387-29.98-33.35-35.70986.04-35.575-29.202NANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
 us-gaap:AllocatedShareBasedCompensationExpense us-gaap:IncomeStatementLocation us-gaap:GeneralAndAdministrativeExpense▄▄▄▃▄▄▄▄▄▄▁▆▇▇▇▇▇▆▆█▆0.4510.4470.4410.3750.4350.4880.4890.4740.6050.486-0.8741.4522.1692.2632.2922.2522.3291.7321.5752.6691.689NANA1.59NANANANANANANANANANANANANANANANANA
us-gaap:ComprehensiveIncomeNetOfTax ▄▄▃▄▄▃▃▃▃█▃▄▃▄▃▃▃▃▃▃▃▃▂▂▂▂▂▁▁▁▁▂▂▂▂▂▄▂▂▂▂94.12353.90328.2276.80965.44345.95139.80137.76333.803263.7647.09654.63829.57758.3723.76435.14716.84325.46415.03514.6044.4364.288-4.563-7.808-10.592-15.816-25.174-60.029-67.694-49.969-46.768-36.536-37.367-31.341-34.467-37.2284.569-37.048-30.643-25.081-22.672
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest ▆█▅█▅▅▃▄▃▃▂▂▁▁▁▁▁15.57221.11313.40321.38113.51511.9137.2428.3216.2295.4553.0781.990.7490.1290.00.00.0NANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest ▄▃▂▃▃▂▂▂▂█▂▂▁▂▁▂▁109.69575.01641.62398.1978.95857.86447.04346.08440.032269.21550.17456.62830.32658.49923.76435.14716.843NANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:GainLossOnInvestments █▄▁▇▅55.04511.032-29.36846.69821.915NANA0.00.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:GeneralAndAdministrativeExpense ▄▄▂▁▁▁▃▃▂▁▂▃▇▁▆██▄▃▄▄▃▃▃▄▄▆▆5.9865.473.2542.5962.5632.3324.9624.3473.0152.6384.0194.4118.9852.7698.3110.38410.7955.6065.1056.2256.2524.8214.5814.9095.4396.3738.6328.603NA6.4076.01811.374NA7.6587.7547.597.8578.4687.7967.2487.169
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest █▅▁▇▅▃▂▂▁129.43190.75850.487118.11694.88470.26557.60956.49448.527NANANA30.33NANANANANANANANA4.301-4.584NANA-15.926-21.549-19.873NA-8.894-9.454-1.541NANANANANANANANANA
us-gaap:IncomeTaxExpenseBenefit █████████▁▇▇▇▇▇▇▇19.73615.7428.86619.89115.93212.40310.55810.4338.508-196.0730.00.00.00.0040.00.00.0NANANANA0.00.0NANA0.0-0.2780.278NA0.00.00.0NANANANANANANANANA
us-gaap:InterestExpense ▃▃▃▃▃▃▃▃▃▃▃▄▅▅▆▇███████████▆▁▁▁▂▂▁▁▁▁▁▁▁▁4.6944.6514.6034.5614.5164.6894.6934.6614.6174.5815.2386.4787.6578.35410.26212.20412.78113.013.10313.15613.15713.04713.06312.98712.70612.56612.35510.3271.6441.6861.9023.0242.7361.51.51.5011.5021.5031.5051.5061.51
 us-gaap:InterestExpenseDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType inva:Percent2.50ConvertibleDebt,inva:SeniorUnsecuredConvertibleNotes███▇▇▇▇▇▇▆▆▆▆▆▁3.2733.2263.1833.1383.0973.0563.0152.9742.9372.8972.8622.8242.7922.7571.625NANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:InterestPaidNet ▄▁▄▁▄▁▄▁▄▁▄▂▆▃▇▇█▇4.9670.04.9660.04.9670.35.2130.2435.2180.2396.7091.9728.9413.79712.24610.78813.52211.068NANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest ▆█▅█▅▅▃▄▃▃▂▂▁▁▁▁▁15.57221.11313.40321.38113.51511.9137.2428.3216.2295.4553.0781.990.7490.1290.00.00.0NANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic ▄▄▃▄▄▃▃▃▃█▃▄▃▄▃▃▃▃▃▃▃▃▂▂▂▂▂▁▁▁▁▂▂▂▂▂94.12353.90328.21876.84465.43745.94939.80937.7433.79263.7647.08954.62629.58158.38523.76735.14616.84525.88315.03314.5974.4354.301-4.584-7.81-10.667-15.926-21.271-63.564-67.703-49.929-46.985-36.429-37.36-31.324-34.692-37.12NA-37.007-30.626-25.045NA
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted ▃▂▂▃▃▂▂▂▂█▂▂▂▂▂▂▁▂▁▁▁95.32755.08529.38978.02866.61747.11540.96638.89835.205265.17948.50256.04330.99359.80125.17736.5618.25231.26116.46216.0544.435NANA-7.81NANANANANANANA-36.429NANA-34.692-37.1286.094NA-30.626-25.045-22.667
us-gaap:OperatingExpenses ▂▂▂▂▂▂▂▂▂▁▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂█▂▆▆▅▅▅▅▅▅▅▄▄6.0355.6894.2643.1552.5632.3324.9624.3473.015-2.6384.0194.41111.6853.1118.62110.73211.1495.5965.3916.5956.6445.5435.1285.5476.1517.1510.54110.72866.4098.8945.67743.11334.73135.77834.7837.13941.05940.93735.63330.04627.633
us-gaap:OperatingIncomeLoss █████▇▇▇▆█▇▇▆▇▆▆▅▆▅▅▅▅▄▄▄▄▄▄▁▂▂▂▃▃▃▂█▂▃▃▃79.48384.78784.4375.79176.11573.63960.79359.7652.16877.2257.66162.67540.69566.40940.02247.8329.34338.01627.91825.87717.53217.2938.4345.1080.7450.13-9.542-9.794-66.244-48.452-45.238-41.786-33.387-29.98-33.35-35.70986.04-35.575-29.202-23.657-21.302
us-gaap:OtherNonoperatingIncomeExpense ▁▁▇▇█▄▅▇▇-0.433-0.433-0.0130.030.068-0.223-0.115-0.0080.001NANA0.039-3.0990.066-6.369-0.7860.0470.6390.0561.719-0.0320.003-0.045-0.0161.178-3.6070.2550.083-0.003-0.002-0.0378.192-1.422NANANANANANANANA
us-gaap:ProfitLoss ▄▃▂▃▃▂▂▂▂█▂▂▂▂▂▂▁▂▁▁▁109.69575.01641.62198.22578.95257.86247.05146.06140.019269.21550.16756.61630.3358.51423.76735.14616.84525.47115.03314.5974.435NANANANANANANANANANANANANANANANANANA-25.045NA
us-gaap:ResearchAndDevelopmentExpense ▁▂█▅0.0490.2191.010.559NANANA0.0NA0.00.00.00.00.3420.3110.3480.3540.3450.2860.370.3920.7220.5470.6380.7120.7771.9092.12543.38733.63133.39531.73926.41628.1227.02629.54933.20232.46927.83722.79820.464
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax ▆▆▆▅▅▅▅▅▄▅▄▅▄▅▄▄▃▃▃▃▂▂▂▂▁▁▁▁▁▁▁▁▁▁▁▁█▁▁▁▁85.51890.47688.69478.94678.67875.97165.75564.10755.18379.85861.6867.08652.3869.5248.64358.56240.49243.61233.30932.47224.17622.83613.56210.6556.8967.280.9990.9340.1651.4730.4151.3221.3445.7981.431.43127.0995.3626.4316.3896.331
us-gaap:Revenues ▆▆▆▅▅▅▅▅▄▅▄▅▄▅▄▄▃▃▃▃▂▂▂▂▁▁▁▁▁▁▁▁▁▁▁▁█▁▁▁▁85.51890.47688.69478.94678.67875.97165.75564.10755.18379.85861.6867.08652.3869.5248.64358.56240.49243.61233.30932.47224.17622.83613.56210.6556.8967.280.9990.9340.1651.4730.4151.3221.3445.7981.431.43127.0995.3626.4316.3896.331
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:Assets █▆▅▄▂▁1088.29999.57922.256879.619788.011724.826NANA590.114548.193277.693338.692276.745367.337390.972NA391.872378.996NA378.109387.829424.072437.631NANA521.654553.713605.61605.034681.255666.016594.704NA368.582383.943399.422217.727258.782NA303.12NA
us-gaap:LiabilitiesAndStockholdersEquity █▆▅▄▂▁1088.29999.57922.256879.619788.011724.826NANA590.114548.193277.693338.692276.745367.337390.972NA391.872378.996NA378.109387.829424.072437.631NANA521.654553.713605.61605.034681.255666.016594.704NA368.582383.943399.422217.727258.782NA303.12NA
us-gaap:StockholdersEquity █▆▅▄▂▁634.461539.912485.556456.907379.543313.495NANA188.245153.583-111.357-157.356-213.558-242.859-222.961NA-334.186-352.991NA-363.102-361.969-342.645-322.999NANA-223.349-193.136-187.526263.252299.122330.04985.647NA155.028173.288189.2566.131-87.052NANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:AssetsCurrent ▂▁█▆▅▄372.933342.058572.041500.193466.907431.234NANA251.519199.043121.129178.66113.245200.369220.509NA214.418198.046NA190.421196.706214.325223.754NANA252.182273.471353.163389.196483.198522.341457.233NA261.133282.535303.38204.327244.763NA288.625NA
us-gaap:CashAndCashEquivalentsAtCarryingValue ▂▁█▆▄▂282.89246.487479.193413.147351.981278.096NANA65.15162.41748.61587.22627.13873.336138.417127.634159.808118.01693.194112.945151.778159.1878.746149.579141.18696.8119.575208.052125.275143.51171.892199.243266.0794.849112.235161.09614.3144.77862.73690.658147.874
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents ▅▄█▇▆▅▃▃▁▁▁282.89246.487479.193413.147351.981278.096172.946141.95265.15162.41748.615NA27.13873.336138.417NANA118.016NANANA159.18NANANANANANANANANANANANANANANANANANANA
us-gaap:PrepaidExpenseAndOtherAssetsCurrent ▄█▁▁▂▃1.0691.640.6980.6450.8220.962NANA0.7020.8490.5130.5760.950.7540.439NA0.880.766NA0.7380.9750.8140.615NANA1.1340.7480.9826.3914.2874.0713.609NA3.9663.7723.3983.93.525NA4.506NA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
 us-gaap:AssetsNoncurrent us-gaap:ConsolidatedEntities inva:ArmataPharmaceuticalsIncNANA28.651NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:AssetsNoncurrent us-gaap:ConsolidatedEntities inva:EntasisTherapeuticsHoldingsIncNANA1.564NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:PropertyPlantAndEquipmentNet ▁▃▄▆█▄0.0240.0280.0330.0370.0420.033NANA0.1480.160.1730.1850.1970.2090.249NA0.3280.368NA0.1740.1930.2210.248NANA0.3240.0640.09.73410.2388.5638.952NA9.1549.5799.6610.05910.372NA10.334NA
us-gaap:LongTermInvestments █▁519.325438.258NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:DeferredTaxAssetsLiabilitiesNet NA93.759NANANA154.171NANANA196.054NANANA0.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherAssetsNoncurrent ▁▂▄▅▇█0.1880.2140.2390.2640.2880.312NANA0.0370.0370.0370.0370.0370.0370.037NA0.0370.037NA0.0580.01815.15815.805NANA18.10119.94722.3857.9637.3555.9467.372NA2.1281.8942.1012.3082.514NA2.928NA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities inva:Imaginab6.4NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:ArmataPharmaceuticalsInc,inva:CommonStockAndWarrants█▁125.344.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:ArmataPharmaceuticalsInc,us-gaap:CommonStock█▁71.126.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:ArmataPharmaceuticalsInc,us-gaap:Warrant█▁54.218.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:EntasisTherapeuticsHoldingsInc,inva:CommonStockAndWarrants▁█66.678.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:EntasisTherapeuticsHoldingsInc,us-gaap:CommonStock▁█40.046.1NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:EntasisTherapeuticsHoldingsInc,us-gaap:Warrant▁█26.631.9NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:Incarda,inva:SeriesCPreferredStockAndWarrants15.8NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:FinancialInstrument inva:Incarda,us-gaap:Warrant▁█0.71.1NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities,us-gaap:SubsequentEventType inva:TheravanceRespiratoryCompanyLlc,us-gaap:SubsequentEventNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName,us-gaap:FinancialInstrument inva:ArmataPharmaceuticalsInc,inva:CommonStockAndWarrantsNANA48.060.346.9NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName,us-gaap:FinancialInstrument inva:ArmataPharmaceuticalsInc,us-gaap:CommonStockNANA27.834.127.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName,us-gaap:FinancialInstrument inva:ArmataPharmaceuticalsInc,us-gaap:WarrantNANA20.226.219.9NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName,us-gaap:FinancialInstrument inva:EntasisTherapeuticsHoldingsInc,inva:CommonStockAndWarrantsNANA63.868.3NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName,us-gaap:FinancialInstrument inva:EntasisTherapeuticsHoldingsInc,us-gaap:CommonStockNANA38.141.4NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName,us-gaap:FinancialInstrument inva:EntasisTherapeuticsHoldingsInc,us-gaap:WarrantNANA25.726.9NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:AccountsPayableCurrent ▁▂█▃▂▁0.0140.0660.6230.1950.1220.01NANA0.1440.0110.1090.0580.0660.6010.629NA2.3040.128NA0.1370.5760.8180.154NANA0.00.5731.7995.5467.5835.7334.834NA5.3774.7574.9895.3085.813NA2.165NA
us-gaap:LiabilitiesCurrent ▃█▃▇▁▆3.8046.113.8985.4142.7985.371NANA3.815.74.2996.7774.06634.74232.884NA20.47320.049NA14.62910.62313.49111.278NANA13.75636.09849.99444.14484.40438.66138.646NA29.96627.0925.77625.57545.496NA35.191NA
us-gaap:OtherLiabilitiesCurrent █▇▆▃▂▁1.471.4021.2230.7760.7340.562NANA1.2580.9550.8650.9090.9181.51.157NA3.1831.095NA1.3921.6872.2182.457NANA2.1083.7734.8344.7924.1373.0934.703NA2.0721.8352.0771.9741.946NA1.935NA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
 us-gaap:LiabilitiesNoncurrent us-gaap:ConsolidatedEntities inva:ArmataPharmaceuticalsIncNANA13.986NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LiabilitiesNoncurrent us-gaap:ConsolidatedEntities inva:EntasisTherapeuticsHoldingsIncNANA0.864NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument,us-gaap:LongtermDebtType inva:Percent2.50ConvertibleDebt,inva:SeniorUnsecuredConvertibleNotes█▇▅▄▂▁147.803145.734143.712141.732139.797137.903NANA132.468130.734NANANA124.158122.605NANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LongTermDebtNoncurrent █▇▅▄▂▁387.728385.517383.35381.23379.152377.12NANA384.744382.855381.002486.527484.591574.362578.449NA702.325708.341NA722.287734.513733.131744.085NANA725.636705.109NANA287.5NANANANANANANANANANANA
us-gaap:MinorityInterest ▇█▅▃▁▁62.2267.92549.31635.90526.32628.621NANA11.6985.4693.0811.9920.8110.152NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherLiabilitiesNoncurrent ▁▂▄▅▇█0.0770.1060.1360.1630.1920.219NANA0.3790.5860.6680.7520.8350.941.049NA1.2671.383NA1.6391.7841.8561.847NANA1.7181.531.3NA0.0NANANANANANANANANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo NANA0.109NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo us-gaap:StatementGeographical inva:BurlingameCaliforniaNA0.109NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:StockholdersEquity █▆▅▄▂▁634.461539.912485.556456.907379.543313.495NANA188.245153.583-111.357-157.356-213.558-242.859-222.961NA-334.186-352.991NA-363.102-361.969-342.645-322.999NANA-223.349-193.136-187.526263.252299.122330.04985.647NA155.028173.288189.2566.131-87.052NANANA
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest █▇▇▆▆▅▅▅▄▄▂▂▁▁696.681607.837534.872492.812405.869342.116283.763246.702199.943159.052-108.276-155.364-212.747-242.707NANANA-352.991NANANA-342.645NANANA-223.349NANANANANANANANANANANANANA-37.482NA
us-gaap:CommonStockValue ▅▅▅█▁▁1.0141.0141.0141.0151.0131.013NANA1.0121.0111.0111.0151.0141.0191.08NA1.0931.085NA1.1161.1321.149NANANA1.1641.1541.1331.1251.1151.1051.008NA0.9840.9790.9690.8650.855NANANA
us-gaap:AdditionalPaidInCapitalCommonStock █▇▆▄▃▁1261.3261260.91260.4471260.0171259.4641258.859NANA1257.1251256.2671258.351259.4431257.881258.1511336.358NA1284.0311282.077NA1312.4341328.1551351.8981375.805NANA1452.5041466.9111444.1051834.8621803.0481784.0161492.945NA1488.4471475.3711456.8821236.6411228.037NA1210.006NA
us-gaap:RetainedEarningsAccumulatedDeficit █▆▅▄▂▁-627.879-722.002-775.905-804.123-880.967-946.404NANA-1069.902-1103.692-1367.452-1414.541-1469.167-1498.748-1557.133NA-1616.046-1632.891NA-1673.395-1687.992-1692.427-1696.728NANA-1673.667-1657.741-1636.47-1572.906-1505.203-1455.274-1408.291NA-1334.502-1303.178-1268.486-1231.366-1315.96NA-1248.328NA
us-gaap:MinorityInterest ▇█▅▃▁▁62.2267.92549.31635.90526.32628.621NANA11.6985.4693.0811.9920.8110.152NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0.451NA0.4410.3750.435NA0.4890.4740.605NANANA2.169NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders 21.285NANA12.15215.81NA10.553NANANANANA0.09NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:NetCashProvidedByUsedInOperatingActivities ██▇█▇▇▆▆▇▆▆▆▆▆▅▄▄▄▄▃▃▃▃▃▂▂▁84.10785.2874.55879.79473.48166.90557.40256.49676.65561.77760.11551.72549.91447.85943.4922.63927.76121.08620.18812.467.256.9172.6562.174-1.616-4.61-21.071NANA-39.974-41.311NANANANANANANANANANA
us-gaap:NetCashProvidedByUsedInInvestingActivities ▆▁▆▆▇▇▆▇▅▆▇▆▇▆▆▆▇▇▆▆▇█▆▇█▆▅-26.394-315.481-8.5-7.016.04451.994-15.93720.107-74.167-45.59413.5229.07826.513-25.88-21.7742.02322.39523.32-15.095-24.49811.69399.288-47.87534.04573.71-8.411-59.545NANA-1.426-99.609NANANANANANANANANANA
us-gaap:NetCashProvidedByUsedInFinancingActivities ▇██▇▇▇▇███▂█▁▃▇▅█▇▇▆▆▇▇▆▆▇█-21.31-2.505-0.012-11.628-15.64-13.749-10.4710.1980.246-2.381-112.248-0.715-122.625-87.06-10.933-56.836-8.364-19.584-24.844-26.795-26.345-25.771-25.614-27.826-27.708-9.754-7.861NANA13.018113.569NANANANANANANANANANA
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect ▇▁▇▇▇█▆▇▆▆36.403-232.70666.04661.16673.885105.1530.99476.8012.73413.802NANA-46.198-65.081NANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
 us-gaap:AmortizationOfFinancingCosts us-gaap:DebtInstrument,us-gaap:LongtermDebtType inva:Percent2.50ConvertibleDebt,inva:SeniorUnsecuredConvertibleNotes██▇▇▇▇▆▆▆▆▆▅▅▅▁0.1590.1550.1520.1490.1450.1430.1390.1360.1330.130.1270.1250.1230.120.069NANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:DeferredIncomeTaxExpenseBenefit █▅▁█▆▃▂▂▁19.73615.7318.86619.89115.93212.37610.55910.4328.508NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:DepreciationDepletionAndAmortization ██████▇███████████████████▄▅▇▄▂▂▂▂▂▁▂▃▂▁▁3.463.4583.4613.4583.4633.4743.323.5413.5393.4683.4683.4683.4683.4953.4963.4953.4963.4963.4913.4843.4833.4843.4833.4833.4833.4552.532.793.42.5191.7941.9921.8981.8641.891.6621.912.1242.0521.7571.65
us-gaap:IncreaseDecreaseInAccountsPayable ▆▅▆▆▆▆▅▇▆▆▆▆▅▆▆▄█▅▆▅▆▆▅▅▇▅▄▁▅▅▇▇▆▅▅▆▆█▆▆▆-0.052-0.5570.4280.0730.112-0.025-1.1040.9950.133-0.0980.051-0.008-0.535-0.0280.352-2.0272.176-0.40.391-0.439-0.2420.664-0.308-0.5631.025-0.573-1.29-4.658-1.174-0.4271.0141.247-0.221-1.028-0.371-0.1290.0481.8640.6330.6150.198
us-gaap:NetCashProvidedByUsedInOperatingActivities ██▇█▇▇▆▆▇▆▆▆▆▆▅▄▄▄▄▃▃▃▃▃▂▂▁84.10785.2874.55879.79473.48166.90557.40256.49676.65561.77760.11551.72549.91447.85943.4922.63927.76121.08620.18812.467.256.9172.6562.174-1.616-4.61-21.071NANA-39.974-41.311NANANANANANANANANANA
us-gaap:ProfitLoss ▄▃▂▃▃▂▂▂▂█▂▂▂▂▂▂▁▂▁▁▁109.69575.01641.62198.22578.95257.86247.05146.06140.019269.21550.16756.61630.3358.51423.76735.14616.84525.47115.03314.5974.435NANANANANANANANANANANANANANANANANANA-25.045NA
us-gaap:ShareBasedCompensation ▂▂▂▂▂▂▂▂▂▂▁▂▂▃▃▃▃▂▂▃▂▂▂▂▂▂▄▅█▄▅▅▄▄▄▄▄▄▅▄▄0.4510.4470.4410.3750.4350.4880.4890.4740.6050.486-0.8741.4522.1692.4272.4722.4272.5071.8741.7182.8411.8641.651.4681.8221.9331.3774.7327.74613.5355.9836.4477.1626.0955.7395.835.9796.2356.217.5725.5935.541
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:NetCashProvidedByUsedInInvestingActivities ▆▁▆▆▇▇▆▇▅▆▇▆▇▆▆▆▇▇▆▆▇█▆▇█▆▅-26.394-315.481-8.5-7.016.04451.994-15.93720.107-74.167-45.59413.5229.07826.513-25.88-21.7742.02322.39523.32-15.095-24.49811.69399.288-47.87534.04573.71-8.411-59.545NANA-1.426-99.609NANANANANANANANANANA
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment NA0.00.00.00.013NANA0.00.0NANANANA0.0NANANA0.0280.2420.0080.00.0010.00.00.0060.1330.0-1.0641.621.0670.2360.6910.740.2610.5670.6591.1030.905-0.041.3821.381
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
us-gaap:NetCashProvidedByUsedInFinancingActivities ▇██▇▇▇▇███▂█▁▃▇▅█▇▇▆▆▇▇▆▆▇█-21.31-2.505-0.012-11.628-15.64-13.749-10.4710.1980.246-2.381-112.248-0.715-122.625-87.06-10.933-56.836-8.364-19.584-24.844-26.795-26.345-25.771-25.614-27.826-27.708-9.754-7.861NANA13.018113.569NANANANANANANANANANA
  2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-31
Value1014000.01014000.01014000.01015000.01013000.01013000.01012000.01011000.01011000.01015000.01014000.01019000.01080000.01093000.01085000.01116000.01132000.01149000.01164000.01154000.01133000.01125000.01115000.01105000.01008000.0984000.0979000.0969000.0865000.0855000.0
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.10.10.10.10.10.20.20.40.30.40.30.30.30.30.30.30.30.20.20.20.20.20.20.20.30.30.20.40.3

Common Stock Shares Issued

us-gaap:CommonStockSharesIssued

us-gaap:CommonStockSharesIssued


Common
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302013-12-31
Value101101101101101101101101101101101102108109108111113114117116115111
Percentage of CommonStockSharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Preferred Stock Shares Authorized

us-gaap:PreferredStockSharesAuthorized

us-gaap:PreferredStockSharesAuthorized


Preferred
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312013-12-312012-12-312011-12-31
Value230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0230000.0500000.0230000.0230000.0
Percentage of PreferredStockSharesAuthorized100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Common Stock Shares Outstanding

us-gaap:CommonStockSharesOutstanding

us-gaap:CommonStockSharesOutstanding


Common
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-31
Value1011011011011011011011011131121111101009897968685
Percentage of CommonStockSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CommonStockSharesOutstanding us-gaap:StatementEquityComponents

us-gaap:CommonStock


Common
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value10110110110110110110110110110110110210811411611198
Percentage of CommonStockSharesOutstanding100.0100.0100.0100.0100.0100.00.00.0100.0100.00.00.00.00.00.0100.0100.0

Weighted Average Number Of Diluted Shares Outstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding


Weighted
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-09-302016-06-302016-03-312015-06-302015-03-312013-09-302013-06-302012-09-302012-06-302012-03-312011-09-302011-06-302011-03-312010-06-30
Value1131131131131131131131131131131191201201211241131151141069795899282818073
Percentage of WeightedAverageNumberOfDilutedSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Shares Outstanding Basic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic


Weighted
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-09-302016-06-302016-03-312015-06-302015-03-312013-09-302013-06-302012-09-302012-06-302012-03-312011-09-302011-06-302011-03-312010-06-30
Value1011011011011011011011001001001061071071091111121151141069795898382818073
Percentage of WeightedAverageNumberOfSharesOutstandingBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

inva:EquityIncentivePlansAndESPP


Antidilutive
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-09-302016-06-302016-03-312015-06-302015-03-31
Value1.1591.2681.1541.0941.1441.1881.0531.5571.6331.4921.7792.0193.0623.8814.2763.9177.1785.866
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareBasic


Earnings
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302015-03-312013-09-302013-06-302012-09-302012-06-302012-03-312011-09-302011-06-302011-03-31
Value0.930.530.280.760.650.450.390.370.332.610.470.540.290.550.220.330.160.240.140.130.04-0.07-0.09-0.44-0.37-0.37-0.421.01-0.37-0.31-0.28
Percentage of EarningsPerShareBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Diluted

us-gaap:EarningsPerShareDiluted

us-gaap:EarningsPerShareDiluted


Earnings
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302015-03-312013-09-302013-06-302012-09-302012-06-302012-03-312011-09-302011-06-302011-03-31
Value0.840.490.260.690.590.420.360.340.312.340.430.490.270.50.210.30.150.220.130.130.04-0.07-0.09-0.44-0.37-0.37-0.420.93-0.37-0.31-0.28
Percentage of EarningsPerShareDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Allocated Share Based Compensation Expense

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:IncomeStatementLocation

us-gaap:AllocatedShareBasedCompensationExpense

us-gaap:GeneralAndAdministrativeExpense


Allocated
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-30
Value0.4510.4470.4410.3750.4350.4880.4890.4740.6050.486-0.8741.4522.1692.2632.2922.2522.3291.7321.5752.6691.6891.59
Percentage of AllocatedShareBasedCompensationExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.00.50.50.60.60.70.71.10.6-1.42.24.13.34.73.85.84.04.78.27.014.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:GeneralAndAdministrativeExpense0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


Comprehensive
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value945328766545393733263475429582335162515144.4364.288-4.563-7.808-10.592-15.816-25.174-60.029-67.694-49.969-46.768-36.536-37.367-31.341-34.467-37.2284-37.048-30.643-25.081-22.672
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax110.10.031.897.383.260.560.558.961.3330.376.481.456.584.048.960.041.658.445.145.018.318.8-33.6-73.3-153.6-217.3-2519.9-6427.1-41026.7-3392.3-11269.4-2763.7-2780.30.0-2410.3-2602.866.50.0-476.5-392.6-358.1

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest


Comprehensive
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1521132113117.2428.3216.2295.4553.0781.990.7490.1290.00.00.0
Percentage of ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.20.015.127.117.215.711.013.011.36.85.03.01.40.20.00.00.0

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest


Comprehensive
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value109754198785747464026950563058233516
Percentage of ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax128.30.046.9124.4100.476.271.571.972.5337.181.384.457.984.148.960.041.6

Gain Loss On Investments

us-gaap:GainLossOnInvestments

us-gaap:GainLossOnInvestments


Gain
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-06-302019-03-31
Value5511-29.36846210.00.0
Percentage of GainLossOnInvestments100.0100.0100.0100.0100.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax64.40.0-33.159.227.90.00.0

us-gaap:GainLossOnInvestments us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Gain
Period End2021-03-31
Value-0.483
Percentage of GainLossOnInvestments-0.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc-2.2

us-gaap:GainLossOnInvestments us-gaap:CounterpartyName

inva:ArmataPharmaceuticalsInc


Gain
Period End2020-09-302020-06-302020-03-31
Value-12.41321
Percentage of GainLossOnInvestments42.228.799.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-14.017.027.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:ArmataPharmaceuticalsInc0.00.00.0

inva:EntasisTherapeuticsHoldingsInc


Gain
Period End2020-09-302020-06-30
Value-17.033
Percentage of GainLossOnInvestments57.971.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-19.242.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:EntasisTherapeuticsHoldingsInc0.00.0

General And Administrative Expense

us-gaap:GeneralAndAdministrativeExpense

us-gaap:GeneralAndAdministrativeExpense


General
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-06-30
Value5.9865.473.2542.5962.5632.3324.9624.3473.0152.6384.0194.4118.9852.7698.3110105.6065.1056.2256.2524.8214.5814.9095.4396.3738.6328.6036.4076.018117.6587.7547.597.8578.4687.7967.2487.1696.991
Percentage of GeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.00.03.73.33.33.17.56.85.53.36.56.617.24.017.117.726.712.915.319.225.921.133.846.178.987.5864.1921.1435.01450.1860.40.0542.2530.86.20.0121.2113.4113.20.0

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest


Income
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-03-312015-12-312015-09-302014-12-312014-09-302014-06-302013-12-312013-09-302013-06-30
Value12990501189470575648304.301-4.584-15.926-21.549-19.873-8.894-9.454-1.541
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax151.30.056.9149.6120.692.587.688.187.957.918.8-33.8-218.8-2157.1-2127.7-603.8-2278.1-116.6

Income Tax Expense Benefit

us-gaap:IncomeTaxExpenseBenefit

us-gaap:IncomeTaxExpenseBenefit


Income
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312015-12-312015-09-302014-12-312014-09-302014-06-302013-12-312013-09-302013-06-30
Value19158.86619151210108.508-196.0730.00.00.00.0040.00.00.00.00.00.0-0.2780.2780.00.00.0
Percentage of IncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0100.00.00.00.00.00.00.0100.0100.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.10.010.025.220.216.316.116.315.4-245.50.00.00.00.00.00.00.00.00.00.0-27.829.80.00.00.0

Interest Expense

us-gaap:InterestExpense

us-gaap:InterestExpense


Interest
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-06-30
Value4.6944.6514.6034.5614.5164.6894.6934.6614.6174.5815.2386.4787.6578.35410121213131313131312121212101.6441.6861.9023.0242.7361.51.51.5011.5021.5031.5051.5061.511.508
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.50.05.25.85.76.27.17.38.45.78.59.714.612.021.120.831.629.839.340.554.457.196.3121.9184.3172.61236.71105.7996.4114.5458.3228.7203.60.0104.9105.01.20.023.423.623.90.0

Interest Expense Debt

us-gaap:InterestExpenseDebt us-gaap:DebtInstrument, us-gaap:LongtermDebtType

us-gaap:InterestExpenseDebt

inva:Percent2.50ConvertibleDebt, inva:SeniorUnsecuredConvertibleNotes


Interest
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value3.2733.2263.1833.1383.0973.0563.0152.9742.9372.8972.8622.8242.7922.7571.625
Percentage of InterestExpenseDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.80.03.64.03.94.04.64.65.33.64.64.25.34.03.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:Percent2.50ConvertibleDebt inva:SeniorUnsecuredConvertibleNotes0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Interest Paid Net

us-gaap:InterestPaidNet

us-gaap:InterestPaidNet


Interest
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
Value4.9670.04.9660.04.9670.35.2130.2435.2180.2396.7091.9728.9413.79712101311
Percentage of InterestPaidNet100.00.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.80.05.60.06.30.47.90.49.50.310.92.917.15.525.218.433.425.4

Net Income Loss Attributable To Noncontrolling Interest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1521132113117.2428.3216.2295.4553.0781.990.7490.1290.00.00.0
Percentage of NetIncomeLossAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.20.015.127.117.215.711.013.011.36.85.03.01.40.20.00.00.0

Net Income Loss Available To Common Stockholders Basic

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302011-12-312011-09-302011-06-30
Value945328766545393733263475429582335162515144.4354.301-4.584-7.81-10.667-15.926-21.271-63.564-67.703-49.929-46.985-36.429-37.36-31.324-34.692-37.12-37.007-30.626-25.045
Percentage of NetIncomeLossAvailableToCommonStockholdersBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax110.10.031.897.383.260.560.558.961.2330.376.381.456.584.048.960.041.659.345.145.018.318.8-33.8-73.3-154.7-218.8-2129.2-6805.6-41032.1-3389.6-11321.7-2755.6-2779.80.0-2426.0-2595.80.0-476.2-392.0

Net Income Loss Available To Common Stockholders Diluted

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302013-06-302012-09-302012-06-302012-03-312011-09-302011-06-302011-03-31
Value955529786647403835265485630592536183116164.435-7.81-36.429-34.692-37.1286-30.626-25.045-22.667
Percentage of NetIncomeLossAvailableToCommonStockholdersDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax111.50.033.198.884.762.062.360.763.8332.178.683.559.286.051.862.445.171.749.449.418.3-73.3-2755.6-2426.0-2595.867.7-476.2-392.0-358.0

Operating Expenses

us-gaap:OperatingExpenses

us-gaap:OperatingExpenses


Operating
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-06-30
Value6.0355.6894.2643.1552.5632.3324.9624.3473.015-2.6384.0194.411113.1118.62110115.5965.3916.5956.6445.5435.1285.5476.1517.151010668.89454334353437414035302725
Percentage of OperatingExpenses100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.10.04.84.03.33.17.56.85.5-3.36.56.622.34.517.718.327.512.816.220.327.524.337.852.189.298.21055.21148.640247.9603.511006.53261.22584.20.02432.22597.132.30.0554.1470.3436.50.0

us-gaap:OperatingExpenses us-gaap:ConsolidatedEntities

inva:PulmoquineTherapeuticsInc.


Operating
Period End2020-12-312020-09-302020-06-30
Value0.31.10.6
Percentage of OperatingExpenses5.325.819.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.01.20.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:PulmoquineTherapeuticsInc.0.00.00.0

inva:TheravanceRespiratoryCompanyLlc


Operating
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value3.2811.2120.60.50.2710.482.8
Percentage of OperatingExpenses54.421.314.115.810.620.656.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.80.00.70.60.30.64.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc14.90.03.73.21.70.025.0

Operating Income Loss

us-gaap:OperatingIncomeLoss

us-gaap:OperatingIncomeLoss


Operating
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-06-30
Value798484757673605952775762406640472938272517178.4345.1080.7450.13-9.542-9.794-66.244-48.452-45.238-41.786-33.387-29.98-33.35-35.70986-35.575-29.202-23.657-21.302-19.432
Percentage of OperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax92.90.095.296.096.796.992.593.294.596.793.593.477.795.582.381.772.587.283.879.772.575.762.247.910.81.8-955.2-1048.6-40147.9-3289.3-10900.7-3160.8-2484.20.0-2332.2-2497.167.70.0-454.1-370.3-336.50.0

us-gaap:OperatingIncomeLoss us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Operating
Period End2021-03-312020-03-31
Value1815
Percentage of OperatingIncomeLoss23.720.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax22.020.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc85.198.3

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:OtherNonoperatingIncomeExpense


Other
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
Value-433000.0-433000.0-13000.030000.068000.0-223000.0-115000.0-8000.01000.039000.0-3099000.066000.0-6369000.0-786000.047000.0639000.056000.01719000.0-32000.03000.0-45000.0-16000.01178000.0-3607000.0255000.083000.0-3000.0-2000.0-37000.08192000.0-1422000.0
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.50.0-0.00.00.1-0.3-0.2-0.00.00.1-5.90.1-13.1-1.30.11.50.25.3-0.10.0-0.3-0.217.1-49.525.58.9-1.8-0.1-8.9619.7-105.8

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312011-06-302010-06-30
Value1097541987857474640269505630582335162515144.435-25.045-20.806
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax128.30.046.9124.4100.376.271.671.972.5337.181.384.457.984.248.960.041.658.445.145.018.3-392.00.0

us-gaap:ProfitLoss us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Profit
Period End2021-03-312020-03-31
Value1815
Percentage of ProfitLoss16.720.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax21.420.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc83.098.5

us-gaap:ProfitLoss us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Profit
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value151321137.2428.3216.2290.749
Percentage of ProfitLoss14.232.221.817.115.418.115.62.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.215.127.117.211.013.011.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Profit
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value9428766539373329
Percentage of ProfitLoss85.867.878.282.984.681.984.497.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax110.131.897.383.260.558.961.256.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.0

Research And Development Expense

us-gaap:ResearchAndDevelopmentExpense

us-gaap:ResearchAndDevelopmentExpense


Research
Period End2021-03-312020-12-312020-09-302020-06-302019-06-302018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-06-30
Value0.0490.2191.010.5590.00.00.00.00.00.3420.3110.3480.3540.3450.2860.370.3920.7220.5470.6380.7120.7771.9092.1254333333126282729333227222018
Percentage of ResearchAndDevelopmentExpense100.0100.0100.0100.00.00.00.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.01.10.70.00.00.00.00.00.50.60.60.90.80.91.11.63.24.06.010.310.7191.1227.526295.22283.28047.02400.81965.50.01889.92066.426.10.0432.9356.8323.20.0

Revenue From Contract With Customer Excluding Assessed Tax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax


Revenue
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value8590887878756564557961675269485840433332242213106.8967.280.9990.9340.1651.4730.4151.3221.3445.7981.431.431275.3626.4316.3896.331
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Revenue
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-30
Value223416151614119.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax25.838.718.519.820.518.917.015.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax25.838.718.519.820.518.917.015.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ConsolidatedEntities, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

inva:TheravanceRespiratoryCompanyLlc, inva:CollaborativeArrangements, inva:MabaProgram


Revenue
Period End2020-09-302020-06-30
Value0.010.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.012.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.012.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc inva:CollaborativeArrangements inva:MabaProgram0.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService

inva:CollaborativeArrangements


Revenue
Period End2020-12-312020-09-302020-06-302019-06-302018-12-312018-09-302017-12-312017-09-30
Value0.00.010.00.00.00.02.4360.221
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.012.70.00.00.03.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.012.70.00.00.03.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:CollaborativeArrangements0.00.0100.00.00.00.0100.0100.0

us-gaap:Royalty


Revenue
Period End2020-12-312020-09-302020-06-302019-12-312019-09-302019-06-302018-12-312018-09-302017-12-312017-09-30
Value90886875656479616748
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.087.3100.0100.0100.0100.0100.096.599.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.087.3100.0100.0100.0100.0100.096.599.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Royalty100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty

us-gaap:Royalty, inva:GSK


Revenue
Period End2020-12-312020-09-302020-06-302019-12-312019-09-302019-06-302018-12-312018-09-302017-12-312017-09-30
Value90886875656479616748
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.087.3100.0100.0100.0100.0100.096.599.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.087.3100.0100.0100.0100.0100.096.599.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Royalty inva:GSK100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement

inva:CollaborativeArrangements, inva:GSK, inva:StrategicAllianceAgreement


Revenue
Period End2020-12-312020-09-302020-06-302019-06-302018-12-312018-09-302017-12-312017-09-30
Value0.00.010.00.00.00.02.4360.221
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.012.70.00.00.03.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.012.70.00.00.03.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:CollaborativeArrangements inva:GSK inva:StrategicAllianceAgreement0.00.0100.00.00.00.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RelatedPartyTransactionsByRelatedParty

inva:GSK


Revenue
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-03-31
Value8590887878756564557961675269485840433324
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:GSK100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Revenues

us-gaap:Revenues

us-gaap:Revenues


Revenues
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value8590887878756564557961675269485840433332242213106.8967.280.9990.9340.1651.4730.4151.3221.3445.7981.431.431275.3626.4316.3896.331
Percentage of Revenues100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Assets

us-gaap:Assets

us-gaap:Assets


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value1088999922879788724590548277338276367390391378378387424437521553605605681666594368383399217258303331
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Assets us-gaap:ConsolidatedEntities

inva:IspFundLp


Assetsus-gaap:
Period End2021-03-312020-12-31
Value304299
Percentage of Assets28.029.9
Percentage of Assets28.029.9
Percentage of Assets inva:IspFundLp100.0100.0

inva:PulmoquineTherapeuticsInc.


Assetsus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-30
Value3.33.54.64.9
Percentage of Assets0.30.40.50.6
Percentage of Assets0.30.40.50.6
Percentage of Assets inva:PulmoquineTherapeuticsInc.100.0100.0100.0100.0

inva:TheravanceRespiratoryCompanyLlc


Assetsus-gaap:
Period End2021-03-312020-12-312019-12-31
Value737936
Percentage of Assets6.78.05.1
Percentage of Assets6.78.05.1
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc100.0100.0100.0

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


Liabilities
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value1088999922879788724590548277338276367390391378378387424437521553605605681666594368383399217258303331
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:LiabilitiesAndStockholdersEquity us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Liabilities
Period End2021-03-312020-12-312019-12-31
Value737936
Percentage of LiabilitiesAndStockholdersEquity6.78.05.1
Percentage of Assets6.78.05.1
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc100.0100.0100.0

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312010-12-312009-12-31
Value634539485456379313188153-111.357-157.356-213.558-242.859-222.961-334.186-352.991-363.102-361.969-342.645-322.999-223.349-193.136-187.526263299330851551731896.131-87.052-22.42-188.994
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets58.354.052.651.948.243.331.928.0-40.1-46.5-77.2-66.1-57.0-85.3-93.1-96.0-93.3-80.8-73.8-42.8-34.9-31.043.543.949.614.442.145.147.42.8-33.6-6.80.0

us-gaap:StockholdersEquity us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Stockholders
Period End2020-12-312019-12-31
Value7933
Percentage of StockholdersEquity14.710.7
Percentage of Assets8.04.6
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc99.491.6

Assets Current

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value372342572500466431251199121178113200220214198190196214223252273353389483522457261282303204244288316
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets34.334.262.056.959.359.542.636.343.652.740.954.556.454.752.350.450.750.551.148.349.458.364.370.978.476.970.873.676.093.894.695.295.5

us-gaap:AssetsCurrent us-gaap:ConsolidatedEntities

inva:ArmataPharmaceuticalsInc


Assets
Period End2020-09-30
Value17
Percentage of AssetsCurrent3.0
Percentage of Assets1.8
Percentage of Assets inva:ArmataPharmaceuticalsInc0.0

inva:EntasisTherapeuticsHoldingsInc


Assets
Period End2020-09-30
Value68
Percentage of AssetsCurrent12.0
Percentage of Assets7.4
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc0.0

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


Cash
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-06-302009-12-31
Value28224647941335127865624887277313812715911893112151159781491419611920812514317119926694112161144462901471636947
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets26.024.752.047.044.738.411.011.417.525.89.820.035.40.040.831.10.029.939.137.518.00.00.018.621.634.420.721.125.833.50.025.729.240.36.617.30.029.90.049.30.00.0

us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:ConsolidatedEntities

inva:PulmoquineTherapeuticsInc.


Cash
Period End2020-12-312020-09-30
Value3.24.3
Percentage of CashAndCashEquivalentsAtCarryingValue1.30.9
Percentage of Assets0.30.5
Percentage of Assets inva:PulmoquineTherapeuticsInc.91.493.5

inva:TheravanceRespiratoryCompanyLlc


Cash
Period End2021-03-312020-12-312020-09-302020-06-302019-12-31
Value2838411622
Percentage of CashAndCashEquivalentsAtCarryingValue10.115.48.64.08.0
Percentage of Assets2.63.84.51.93.1
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc38.847.60.00.060.8

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents


Cash
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-302016-12-312015-12-31
Value2822464794133512781721416562482773138118159
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets26.024.752.047.044.738.40.00.011.011.417.59.820.035.431.137.5

Prepaid Expense And Other Assets Current

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent


Prepaid
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value1069000.01640000.0698000.0645000.0822000.0962000.0702000.0849000.0513000.0576000.0950000.0754000.0439000.0880000.0766000.0738000.0975000.0814000.0615000.01134000.0748000.0982000.06391000.04287000.04071000.03609000.03966000.03772000.03398000.03900000.03525000.04506000.05995000.0
Percentage of PrepaidExpenseAndOtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.20.10.10.10.10.10.20.20.20.30.20.10.20.20.20.30.20.10.20.10.21.10.60.60.61.11.00.91.81.41.51.8

us-gaap:PrepaidExpenseAndOtherAssetsCurrent us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Prepaid
Period End2021-03-312019-12-31
Value1000.010000.0
Percentage of PrepaidExpenseAndOtherAssetsCurrent0.11.0
Percentage of Assets0.00.0
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc0.00.0

Assets Noncurrent

us-gaap:AssetsNoncurrent us-gaap:ConsolidatedEntities

us-gaap:AssetsNoncurrent

inva:ArmataPharmaceuticalsInc


Assets
Period End2020-09-30
Value28
Percentage of AssetsNoncurrent100.0
Percentage of Assets3.1
Percentage of Assets inva:ArmataPharmaceuticalsInc0.0

inva:EntasisTherapeuticsHoldingsInc


Assets
Period End2020-09-30
Value1.564
Percentage of AssetsNoncurrent5.5
Percentage of Assets0.2
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc0.0

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


Property
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value0.0240.0280.0330.0370.0420.0330.1480.160.1730.1850.1970.2090.2490.3280.3680.1740.1930.2210.2480.3240.0640.09.734108.5638.9529.1549.5799.6610101010
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.10.10.10.10.10.10.10.00.00.10.10.10.00.01.61.51.31.52.52.52.44.64.03.43.1

Long Term Investments

us-gaap:LongTermInvestments

us-gaap:LongTermInvestments


Long
Period End2021-03-312020-12-31
Value519438
Percentage of LongTermInvestments100.0100.0
Percentage of Assets47.743.8

us-gaap:LongTermInvestments us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Long
Period End2021-03-312020-12-31
Value2216
Percentage of LongTermInvestments4.43.9
Percentage of Assets2.11.7
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc31.221.2

Deferred Tax Assets Liabilities Net

us-gaap:DeferredTaxAssetsLiabilitiesNet

us-gaap:DeferredTaxAssetsLiabilitiesNet


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value931541960.00.0
Percentage of DeferredTaxAssetsLiabilitiesNet100.0100.0100.00.00.0
Percentage of Assets9.421.335.80.00.0

Other Assets Noncurrent

us-gaap:OtherAssetsNoncurrent

us-gaap:OtherAssetsNoncurrent


Other
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value0.1880.2140.2390.2640.2880.3120.0370.0370.0370.0370.0370.0370.0370.0370.0370.0580.01815151819227.9637.3555.9467.3722.1281.8942.1012.3082.5142.9283.34
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.03.63.63.53.63.71.31.10.91.20.60.50.51.11.01.01.0

Equity Securities Fv Ni

us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities

us-gaap:EquitySecuritiesFvNi

inva:Imaginab


Equity
Period End2021-03-31
Value6.4
Percentage of EquitySecuritiesFvNi100.0
Percentage of Assets0.6
Percentage of Assets inva:Imaginab0.0

us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

inva:ArmataPharmaceuticalsInc, inva:CommonStockAndWarrants


Equity
Period End2021-03-312020-12-31
Value12544
Percentage of EquitySecuritiesFvNi1957.80.0
Percentage of Assets11.54.4
Percentage of Assets inva:ArmataPharmaceuticalsInc inva:CommonStockAndWarrants0.00.0

inva:ArmataPharmaceuticalsInc, us-gaap:CommonStock


Equity
Period End2021-03-312020-12-31
Value7126
Percentage of EquitySecuritiesFvNi1110.90.0
Percentage of Assets6.52.6
Percentage of Assets inva:ArmataPharmaceuticalsInc us-gaap:CommonStock0.00.0

inva:ArmataPharmaceuticalsInc, us-gaap:Warrant


Equity
Period End2021-03-312020-12-31
Value5418
Percentage of EquitySecuritiesFvNi846.90.0
Percentage of Assets5.01.8
Percentage of Assets inva:ArmataPharmaceuticalsInc us-gaap:Warrant0.00.0

inva:EntasisTherapeuticsHoldingsInc, inva:CommonStockAndWarrants


Equity
Period End2021-03-312020-12-31
Value6678
Percentage of EquitySecuritiesFvNi1040.60.0
Percentage of Assets6.17.8
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc inva:CommonStockAndWarrants0.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:CommonStock


Equity
Period End2021-03-312020-12-31
Value4046
Percentage of EquitySecuritiesFvNi625.00.0
Percentage of Assets3.74.6
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc us-gaap:CommonStock0.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:Warrant


Equity
Period End2021-03-312020-12-31
Value2631
Percentage of EquitySecuritiesFvNi415.60.0
Percentage of Assets2.43.2
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc us-gaap:Warrant0.00.0

inva:Incarda, inva:SeriesCPreferredStockAndWarrants


Equity
Period End2021-03-31
Value15
Percentage of EquitySecuritiesFvNi246.9
Percentage of Assets1.5
Percentage of Assets inva:Incarda inva:SeriesCPreferredStockAndWarrants0.0

inva:Incarda, us-gaap:Warrant


Equity
Period End2021-03-312020-12-31
Value0.71.1
Percentage of EquitySecuritiesFvNi10.90.0
Percentage of Assets0.10.1
Percentage of Assets inva:Incarda us-gaap:Warrant0.00.0

us-gaap:EquitySecuritiesFvNi us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType

inva:TheravanceRespiratoryCompanyLlc, us-gaap:SubsequentEvent


Equity
Period End2020-10-31
Value15
Percentage of EquitySecuritiesFvNi0.0
Percentage of Assets0.0
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc us-gaap:SubsequentEvent0.0

us-gaap:EquitySecuritiesFvNi us-gaap:CounterpartyName, us-gaap:FinancialInstrument

inva:ArmataPharmaceuticalsInc, inva:CommonStockAndWarrants


Equity
Period End2020-09-302020-06-302020-03-31
Value486046
Percentage of EquitySecuritiesFvNi0.00.00.0
Percentage of Assets5.26.96.0
Percentage of Assets inva:ArmataPharmaceuticalsInc inva:CommonStockAndWarrants0.00.00.0

inva:ArmataPharmaceuticalsInc, us-gaap:CommonStock


Equity
Period End2020-09-302020-06-302020-03-31
Value273427
Percentage of EquitySecuritiesFvNi0.00.00.0
Percentage of Assets3.03.93.4
Percentage of Assets inva:ArmataPharmaceuticalsInc us-gaap:CommonStock0.00.00.0

inva:ArmataPharmaceuticalsInc, us-gaap:Warrant


Equity
Period End2020-09-302020-06-302020-03-31
Value202619
Percentage of EquitySecuritiesFvNi0.00.00.0
Percentage of Assets2.23.02.5
Percentage of Assets inva:ArmataPharmaceuticalsInc us-gaap:Warrant0.00.00.0

inva:EntasisTherapeuticsHoldingsInc, inva:CommonStockAndWarrants


Equity
Period End2020-09-302020-06-30
Value6368
Percentage of EquitySecuritiesFvNi0.00.0
Percentage of Assets6.97.8
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc inva:CommonStockAndWarrants0.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:CommonStock


Equity
Period End2020-09-302020-06-30
Value3841
Percentage of EquitySecuritiesFvNi0.00.0
Percentage of Assets4.14.7
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc us-gaap:CommonStock0.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:Warrant


Equity
Period End2020-09-302020-06-30
Value2526
Percentage of EquitySecuritiesFvNi0.00.0
Percentage of Assets2.83.1
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc us-gaap:Warrant0.00.0

Accounts Payable Current

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


Accounts
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value14000.066000.0623000.0195000.0122000.010000.0144000.011000.0109000.058000.066000.0601000.0629000.02304000.0128000.0137000.0576000.0818000.0154000.00573000.01799000.05546000.07583000.05733000.04834000.05377000.04757000.04989000.05308000.05813000.02165000.02128000.0
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.10.00.00.00.00.00.00.00.00.20.20.60.00.00.10.20.00.00.10.30.91.10.90.81.51.21.22.42.20.70.6

Liabilities Current

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


Liabilities
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value3.8046.113.8985.4142.7985.3713.815.74.2996.7774.06634322020141013111336494484383829272525453540
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.30.60.40.60.40.70.61.01.52.01.59.58.45.25.33.92.73.22.62.66.58.37.312.45.86.58.17.16.511.717.611.612.1

us-gaap:LiabilitiesCurrent us-gaap:ConsolidatedEntities

inva:ArmataPharmaceuticalsInc


Liabilities
Period End2020-09-30
Value7.07
Percentage of LiabilitiesCurrent181.4
Percentage of Assets0.8
Percentage of Assets inva:ArmataPharmaceuticalsInc0.0

inva:EntasisTherapeuticsHoldingsInc


Liabilities
Period End2020-09-30
Value6.862
Percentage of LiabilitiesCurrent176.0
Percentage of Assets0.7
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc0.0

inva:TheravanceRespiratoryCompanyLlc


Liabilities
Period End2021-03-312020-12-312019-12-31
Value0.640.5083.069
Percentage of LiabilitiesCurrent16.88.357.1
Percentage of Assets0.10.10.4
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc0.90.68.4

Other Liabilities Current

us-gaap:OtherLiabilitiesCurrent

us-gaap:OtherLiabilitiesCurrent


Other
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value1470000.01402000.01223000.0776000.0734000.0562000.01258000.0955000.0865000.0909000.0918000.01500000.01157000.03183000.01095000.01392000.01687000.02218000.02457000.02108000.03773000.04834000.04792000.04137000.03093000.04703000.02072000.01835000.02077000.01974000.01946000.01935000.02008000.0
Percentage of OtherLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.10.10.10.10.10.20.20.30.30.30.40.30.80.30.40.40.50.60.40.70.80.80.60.50.80.60.50.50.90.80.60.6

Liabilities Noncurrent

us-gaap:LiabilitiesNoncurrent us-gaap:ConsolidatedEntities

us-gaap:LiabilitiesNoncurrent

inva:ArmataPharmaceuticalsInc


Liabilities
Period End2020-09-30
Value13
Percentage of LiabilitiesNoncurrent100.0
Percentage of Assets1.5
Percentage of Assets inva:ArmataPharmaceuticalsInc0.0

inva:EntasisTherapeuticsHoldingsInc


Liabilities
Period End2020-09-30
Value0.864
Percentage of LiabilitiesNoncurrent6.2
Percentage of Assets0.1
Percentage of Assets inva:EntasisTherapeuticsHoldingsInc0.0

Long Term Debt

us-gaap:LongTermDebt us-gaap:DebtInstrument, us-gaap:LongtermDebtType

us-gaap:LongTermDebt

inva:Percent2.50ConvertibleDebt, inva:SeniorUnsecuredConvertibleNotes


Long
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312017-12-312017-09-30
Value147145143141139137132130124122
Percentage of LongTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets13.614.615.616.117.719.022.423.833.831.4
Percentage of Assets inva:Percent2.50ConvertibleDebt inva:SeniorUnsecuredConvertibleNotes0.00.00.00.00.00.00.00.00.00.0

Long Term Debt Noncurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:LongTermDebtNoncurrent


Long
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302013-12-31
Value387385383381379377384382381486484574578702708722734733744725705287
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets35.638.641.643.348.152.065.269.8137.2143.6175.1156.4148.0179.2186.9191.0189.4172.9170.0139.1127.342.2

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value626749352628115.4693.0811.9920.8110.1520.0
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0
Percentage of Assets5.76.85.34.13.33.92.01.01.10.60.30.00.0

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OtherLiabilitiesNoncurrent


Other
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302013-12-31
Value77000.0106000.0136000.0163000.0192000.0219000.0379000.0586000.0668000.0752000.0835000.0940000.01049000.01267000.01383000.01639000.01784000.01856000.01847000.01718000.01530000.01300000.00
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0
Percentage of Assets0.00.00.00.00.00.00.10.10.20.20.30.30.30.30.40.40.50.40.40.30.30.20.0

Lessee Operating Lease Liability Payments Due Year Two

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo


Lessee
Period End2020-09-30
Value109000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearTwo100.0
Percentage of Assets0.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo us-gaap:StatementGeographical

inva:BurlingameCalifornia


Lessee
Period End2020-12-31
Value109000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearTwo0.0
Percentage of Assets0.0
Percentage of Assets inva:BurlingameCalifornia0.0

Lessee Operating Lease Liability Payments Due

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue


Lessee
Period End2021-03-312020-09-302019-12-31
Value201000.0262000.0348000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDue100.0100.0100.0
Percentage of Assets0.00.00.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue us-gaap:StatementGeographical

inva:BurlingameCalifornia


Lessee
Period End2020-12-31
Value232000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDue0.0
Percentage of Assets0.0
Percentage of Assets inva:BurlingameCalifornia0.0

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312010-12-312009-12-31
Value634539485456379313188153-111.357-157.356-213.558-242.859-222.961-334.186-352.991-363.102-361.969-342.645-322.999-223.349-193.136-187.526263299330851551731896.131-87.052-22.42-188.994
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets58.354.052.651.948.243.331.928.0-40.1-46.5-77.2-66.1-57.0-85.3-93.1-96.0-93.3-80.8-73.8-42.8-34.9-31.043.543.949.614.442.145.147.42.8-33.6-6.80.0

us-gaap:StockholdersEquity us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Stockholders
Period End2020-12-312019-12-31
Value7933
Percentage of StockholdersEquity14.710.7
Percentage of Assets8.04.6
Percentage of Assets inva:TheravanceRespiratoryCompanyLlc99.491.6

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312011-06-302010-12-31
Value696607534492405342283246199159-108.276-155.364-212.747-242.707-352.991-342.645-223.349-37.482-22.42
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets64.060.858.056.051.547.20.00.033.929.0-39.0-45.9-76.9-66.1-93.1-80.8-42.8-12.4-6.8

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-312016-12-312015-12-312014-12-31
Value126112601260126012591258125812571257125612571258128213511452
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest181.0207.4235.7255.7310.3368.0443.5509.8628.7789.8-591.3-518.4-363.2-394.5-650.3
Percentage of Assets115.9126.1136.7143.2159.8173.70.00.0213.0229.2454.5342.5338.3318.8278.4
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStock


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-312016-12-312015-12-312014-12-31
Value1.0141.0141.0141.0151.0131.0131.0131.0131.0121.0111.0141.0191.0851.1491.164
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.10.20.20.20.20.30.40.40.50.6-0.5-0.4-0.3-0.3-0.5
Percentage of Assets0.10.10.10.10.10.10.00.00.20.20.40.30.30.30.2
Percentage of Assets us-gaap:CommonStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:NoncontrollingInterest


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-312016-12-312015-12-312014-12-31
Value6267493526281620115.4690.8110.1520.00.00.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest8.911.29.27.36.58.45.98.15.93.4-0.4-0.1-0.0-0.0-0.0
Percentage of Assets5.76.85.34.13.33.90.00.02.01.00.30.00.00.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-312016-12-312015-12-312014-12-31
Value-627.879-722.002-775.905-804.123-880.967-946.404-992.353-1032.162-1069.902-1103.692-1469.167-1498.748-1632.891-1692.427-1673.667
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-90.1-118.8-145.1-163.2-217.1-276.6-349.7-418.4-535.1-693.9690.6617.5462.6493.9749.4
Percentage of Assets-57.7-72.2-84.1-91.4-111.8-130.60.00.0-181.3-201.3-530.9-408.0-430.8-399.1-320.8
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-31
Value1014000.01014000.01014000.01015000.01013000.01013000.01012000.01011000.01011000.01015000.01014000.01019000.01080000.01093000.01085000.01116000.01132000.01149000.01164000.01154000.01133000.01125000.01115000.01105000.01008000.0984000.0979000.0969000.0865000.0855000.0
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.10.10.10.10.10.20.20.40.30.40.30.30.30.30.30.30.30.20.20.20.20.20.20.20.30.30.20.40.3

Additional Paid In Capital Common Stock

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:AdditionalPaidInCapitalCommonStock


Additional
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value126112601260126012591258125712561258125912571258133612841282131213281351137514521466144418341803178414921488147514561236122812101177
Percentage of AdditionalPaidInCapitalCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets115.9126.1136.7143.2159.8173.7213.0229.2453.1371.9454.5342.5341.8327.7338.3347.1342.5318.8314.4278.4264.9238.5303.3264.7267.9251.0403.8384.3364.7568.0474.5399.2355.5

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


Retained
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value-627880000.0-722000000.0-775900000.0-804120000.0-880970000.0-946400000.0-1069900000.0-1103700000.0-1367500000.0-1414500000.0-1469200000.0-1498700000.0-1557100000.0-1616000000.0-1632900000.0-1673400000.0-1688000000.0-1692400000.0-1696700000.0-1673700000.0-1657700000.0-1636500000.0-1572900000.0-1505200000.0-1455300000.0-1408300000.0-1334500000.0-1303200000.0-1268500000.0-1231400000.0-1316000000.0-1248300000.0-1200600000.0
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-57.7-72.2-84.1-91.4-111.8-130.6-181.3-201.3-492.4-417.6-530.9-408.0-398.3-412.4-430.8-442.6-435.2-399.1-387.7-320.8-299.4-270.2-260.0-220.9-218.5-236.8-362.1-339.4-317.6-565.6-508.5-411.8-362.5

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value626749352628115.4693.0811.9920.8110.1520.0
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0
Percentage of Assets5.76.85.34.13.33.92.01.01.10.60.30.00.0

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue


Adjustments
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value0.4510.4410.3750.4350.4890.4740.6052.169
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.0

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Adjustments
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value0.4510.4410.3750.4350.4890.4740.6052.169
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.0

Minority Interest Decrease From Distributions To Noncontrolling Interest Holders

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders


Minority
Period End2021-03-312020-06-302020-03-312019-09-302018-03-31
Value211215100.09
Percentage of MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.0

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Minority
Period End2021-03-312020-06-302020-03-312019-09-302018-03-31
Value211215100.09
Percentage of MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-312013-09-30
Value84857479736657567661605149474322272120127.256.9172.6562.174-1.616-4.61-21.071-39.974-41.311
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax98.494.384.1101.193.488.187.388.1138.977.497.577.195.368.889.438.768.648.360.638.430.030.319.620.4-23.4-63.3-2109.2-2713.8-9954.5

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-312013-09-30
Value-26.394-315.481-8.5-7.01651-15.93720-74.167-45.594139.07826-25.88-21.7742.0232223-15.095-24.4981199-47.8753473-8.411-59.545-1.426-99.609
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-30.9-348.7-9.6-8.920.468.4-24.231.4-134.4-57.121.913.550.6-37.2-44.83.555.353.5-45.3-75.448.4434.8-353.0319.51068.9-115.5-5960.5-96.8-24002.2

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-312013-09-30
Value-21.31-2.505-0.012-11.628-15.64-13.749-10.4710.1980.246-2.381-112.248-0.715-122.625-87.06-10.933-56.836-8.364-19.584-24.844-26.795-26.345-25.771-25.614-27.826-27.708-9.754-7.86113113
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-24.9-2.8-0.0-14.7-19.9-18.1-15.90.30.4-3.0-182.0-1.1-234.1-125.2-22.5-97.1-20.7-44.9-74.6-82.5-109.0-112.9-188.9-261.2-401.8-134.0-786.9883.827366.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


Cash
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-31
Value36-232.70666617310530762.73413-46.198-65.081
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax42.6-257.274.577.593.9138.447.1119.85.017.3-88.2-93.6

Amortization Of Financing Costs

us-gaap:AmortizationOfFinancingCosts us-gaap:DebtInstrument, us-gaap:LongtermDebtType

us-gaap:AmortizationOfFinancingCosts

inva:Percent2.50ConvertibleDebt, inva:SeniorUnsecuredConvertibleNotes


Amortization
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value159000.0155000.0152000.0149000.0145000.0143000.0139000.0136000.0133000.0130000.0127000.0125000.0123000.0120000.069000.0
Percentage of AmortizationOfFinancingCosts100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Income Tax Expense Benefit

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DeferredIncomeTaxExpenseBenefit


Deferred
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-03-31
Value19158.86619151210108.5080.0
Percentage of DeferredIncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

Depreciation Depletion And Amortization

us-gaap:DepreciationDepletionAndAmortization

us-gaap:DepreciationDepletionAndAmortization


Depreciation
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value3.463.4583.4613.4583.4633.4743.323.5413.5393.4683.4683.4683.4683.4953.4963.4953.4963.4963.4913.4843.4833.4843.4833.4833.4833.4552.532.793.42.5191.7941.9921.8981.8641.891.6621.912.1242.0521.7571.65
Percentage of DepreciationDepletionAndAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Increase Decrease In Accounts Payable

us-gaap:IncreaseDecreaseInAccountsPayable

us-gaap:IncreaseDecreaseInAccountsPayable


Increase
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value-52000.0-557000.0428000.073000.0112000.0-25000.0-1104000.0995000.0133000.0-98000.051000.0-8000.0-535000.0-28000.0352000.0-2027000.02176000.0-400000.0391000.0-439000.0-242000.0664000.0-308000.0-563000.01025000.0-573000.0-1290000.0-4658000.0-1174000.0-427000.01014000.01247000.0-221000.0-1028000.0-371000.0-129000.048000.01864000.0633000.0615000.0198000.0
Percentage of IncreaseDecreaseInAccountsPayable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-312013-09-30
Value84857479736657567661605149474322272120127.256.9172.6562.174-1.616-4.61-21.071-39.974-41.311
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax98.494.384.1101.193.488.187.388.1138.977.497.577.195.368.889.438.768.648.360.638.430.030.319.620.4-23.4-63.3-2109.2-2713.8-9954.5

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312011-06-302010-06-30
Value1097541987857474640269505630582335162515144.435-25.045-20.806
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax128.382.946.9124.4100.376.271.671.972.5337.181.384.457.984.248.960.041.658.445.145.018.3-392.00.0

us-gaap:ProfitLoss us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Profit
Period End2021-03-312020-03-31
Value1815
Percentage of ProfitLoss16.720.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax21.420.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax inva:TheravanceRespiratoryCompanyLlc83.098.5

us-gaap:ProfitLoss us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Profit
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value151321137.2428.3216.2290.749
Percentage of ProfitLoss14.232.221.817.115.418.115.62.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.215.127.117.211.013.011.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Profit
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value9428766539373329
Percentage of ProfitLoss85.867.878.282.984.681.984.497.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax110.131.897.383.260.558.961.256.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.0

Share Based Compensation

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


Share
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value0.4510.4470.4410.3750.4350.4880.4890.4740.6050.486-0.8741.4522.1692.4272.4722.4272.5071.8741.7182.8411.8641.651.4681.8221.9331.3774.7327.746135.9836.4477.1626.0955.7395.835.9796.2356.217.5725.5935.541
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-312013-09-30
Value-26.394-315.481-8.5-7.01651-15.93720-74.167-45.594139.07826-25.88-21.7742.0232223-15.095-24.4981199-47.8753473-8.411-59.545-1.426-99.609
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-30.9-348.7-9.6-8.920.468.4-24.231.4-134.4-57.121.913.550.6-37.2-44.83.555.353.5-45.3-75.448.4434.8-353.0319.51068.9-115.5-5960.5-96.8-24002.2

Payments To Acquire Property Plant And Equipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment


Payments
Period End2020-12-312020-09-302020-06-302020-03-312019-06-302019-03-312017-12-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value00013000.000028000.0242000.08000.001000.0006000.0133000.00-1064000.01620000.01067000.0236000.0691000.0740000.0261000.0567000.0659000.01103000.0905000.0-40000.01382000.01381000.0
Percentage of PaymentsToAcquirePropertyPlantAndEquipment0.00.00.0100.00.00.00.0100.0100.0100.00.0100.00.00.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-312013-09-30
Value-21.31-2.505-0.012-11.628-15.64-13.749-10.4710.1980.246-2.381-112.248-0.715-122.625-87.06-10.933-56.836-8.364-19.584-24.844-26.795-26.345-25.771-25.614-27.826-27.708-9.754-7.86113113
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-24.9-2.8-0.0-14.7-19.9-18.1-15.90.30.4-3.0-182.0-1.1-234.1-125.2-22.5-97.1-20.7-44.9-74.6-82.5-109.0-112.9-188.9-261.2-401.8-134.0-786.9883.827366.0

Effective Income Tax Rate Continuing Operations

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:EffectiveIncomeTaxRateContinuingOperations


Effective
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312017-09-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302015-03-31
Value15.216.830.0020.16817.820.0050.1750.00050.0010.00050.00110.00150.001500
Percentage of EffectiveIncomeTaxRateContinuingOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:EmployeeStockOption


Share
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value1155000.01087000.01237000.01640000.02900000.04262000.05422000.04824000.06120000.06891000.07654000.08414000.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:EmployeeStockOption


Share
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value22.2824.1824.023.923.7223.022.4625.320.318.6216.9116.63
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Assets Net

us-gaap:DeferredTaxAssetsNet

us-gaap:DeferredTaxAssetsNet


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value114166209140.00.00.00.00.0
Percentage of DeferredTaxAssetsNet100.0100.0100.0100.00.00.00.00.00.0

Unrecognized Tax Benefits

us-gaap:UnrecognizedTaxBenefits

us-gaap:UnrecognizedTaxBenefits


Unrecognized
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value151515151515155752464239
Percentage of UnrecognizedTaxBenefits100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Assets Valuation Allowance

us-gaap:DeferredTaxAssetsValuationAllowance

us-gaap:DeferredTaxAssetsValuationAllowance


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Value636364303484463459591521518
Percentage of DeferredTaxAssetsValuationAllowance100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts us-gaap:ProductOrService, us-gaap:Range, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement

inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts

inva:LongActingBeta2AgonistAnoro, srt:Maximum, inva:GSK, inva:LabaCollaboration


Collaborative
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-03-31
Value10.009.900.10.1
Percentage of CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts100.00.0100.00.0100.0100.0

inva:LongActingBeta2AgonistAnoro, srt:Minimum, inva:GSK, inva:LabaCollaboration


Collaborative
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-03-31
Value6.506.43500.0650.065
Percentage of CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts65.00.065.00.065.065.0

inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement

inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne

inva:LongActingBeta2AgonistRelvarBreo, inva:GSK, inva:LabaCollaboration


Collaborative
Period End2021-03-312020-12-31
Value15.00
Percentage of CollaborativeArrangementRoyaltyRateDefinedLevelOne100.00.0

inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement

inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo

inva:LongActingBeta2AgonistRelvarBreo, inva:GSK, inva:LabaCollaboration


Collaborative
Period End2021-03-312020-12-31
Value5.00
Percentage of CollaborativeArrangementRoyaltyRateDefinedLevelTwo100.00.0

inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement

inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate

inva:LongActingBeta2AgonistRelvarBreo, inva:GSK, inva:LabaCollaboration


Collaborative
Period End2021-03-312020-12-312020-09-302020-06-302020-03-31
Value30000.00.00.03000
Percentage of CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate100.00.00.00.0100.0

inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty

inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees

inva:LongActingBeta2AgonistAnoro, inva:GSK


Gross
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-30
Value101311119.851111108.57129.7698.7249.5727.274
Percentage of GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

inva:LongActingBeta2AgonistRelvarBreo, inva:GSK


Gross
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-30
Value5655634556534647426451466044
Percentage of GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees537.0428.2537.7406.9570.0447.8402.1442.7498.7533.4529.7529.1635.1613.2

inva:TrelegyEllipta, inva:GSK


Gross
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-30
Value222416151614119.8427.3296.4343.6220.9520.1790.0
Percentage of GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees210.3191.0137.8139.6163.8121.297.292.585.553.037.110.91.90.0

us-gaap:Royalty, inva:GSK


Gross
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-30
Value8893927282796967588365557051
Percentage of GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees847.4719.2775.5646.5833.8669.0599.3635.3684.2686.4666.8640.0736.9713.2

inva:IncreaseDecreaseInEquitySecuritiesAndLongTermInvestments us-gaap:ConsolidatedEntities

inva:IncreaseDecreaseInEquitySecuritiesAndLongTermInvestments

inva:ArmataPharmaceuticalsInc


Increase
Period End2021-03-312020-03-31
Value6121
Percentage of IncreaseDecreaseInEquitySecuritiesAndLongTermInvestments100.0100.0

inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity

inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity


Net
Period End2020-12-31
Value1000.0
Percentage of NetProceedsFromIssuanceOfVariableInterestEntityEquity100.0

inva:PaymentsToAcquireEquitySecuritiesFvNi us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

inva:PaymentsToAcquireEquitySecuritiesFvNi

inva:EntasisTherapeuticsHoldingsInc, inva:CommonStockAndWarrants


Payments
Period End2020-09-302020-06-30
Value1235
Percentage of PaymentsToAcquireEquitySecuritiesFvNi100.0100.0

inva:Incarda, inva:SeriesCPreferredStockAndWarrants


Payments
Period End2020-10-31
Value15
Percentage of PaymentsToAcquireEquitySecuritiesFvNi0.0

inva:PercentageOfAnnualPerformanceAllocationBasedOnNetProfits us-gaap:ConsolidatedEntities, us-gaap:RelatedPartyTransactionsByRelatedParty

inva:PercentageOfAnnualPerformanceAllocationBasedOnNetProfits

inva:IspFundLp, us-gaap:GeneralPartner


Percentage
Period End2020-12-11
Value10.0
Percentage of PercentageOfAnnualPerformanceAllocationBasedOnNetProfits100.0

inva:PercentageOfEconomicInterestInPartnership us-gaap:ConsolidatedEntities

inva:PercentageOfEconomicInterestInPartnership

inva:IspFundLp


Percentage
Period End2021-03-31
Value100.0
Percentage of PercentageOfEconomicInterestInPartnership100.0

inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements us-gaap:RelatedPartyTransactionsByRelatedParty, us-gaap:TypeOfArrangement

inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements

inva:GSK, inva:LabaCollaboration


Percentage
Period End2021-03-312020-12-31
Value15.00
Percentage of PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements100.00.0

inva:SecuritiesPurchaseAgreementAmount dei:LegalEntity, us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

inva:SecuritiesPurchaseAgreementAmount

inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporation, inva:ArmataPharmaceuticalsInc, inva:CommonStockAndWarrants


Securities
Period End2021-01-26
Value20
Percentage of SecuritiesPurchaseAgreementAmount100.0

inva:SecuritiesPurchaseAgreementAmount us-gaap:ConsolidatedEntities, us-gaap:CounterpartyName, us-gaap:FinancialInstrument

inva:Imaginab, inva:OneOfImaginabsCommonStockholder, us-gaap:CommonStock


Securities
Period End2021-03-18
Value1.3
Percentage of SecuritiesPurchaseAgreementAmount0.0

inva:SecuritiesPurchaseAgreementAmount us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

inva:EntasisTherapeuticsHoldingsInc, inva:CommonStockAndWarrants


Securities
Period End2020-08-272020-04-12
Value1235
Percentage of SecuritiesPurchaseAgreementAmount0.00.0

inva:Imaginab, us-gaap:SeriesCPreferredStock


Securities
Period End2021-03-18
Value4.7
Percentage of SecuritiesPurchaseAgreementAmount0.0

inva:Incarda, inva:SeriesCPreferredStockAndWarrants


Securities
Period End2020-10-06
Value15
Percentage of SecuritiesPurchaseAgreementAmount0.0

inva:SecuritiesPurchaseAgreementAmount us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument, us-gaap:SubsequentEventType

inva:ArmataPharmaceuticalsInc, inva:CommonStockAndWarrants, us-gaap:SubsequentEvent


Securities
Period End2021-01-26
Value20
Percentage of SecuritiesPurchaseAgreementAmount100.0

inva:SecuritiesPurchaseAgreementAmount us-gaap:CounterpartyName, us-gaap:FinancialInstrument

inva:EntasisTherapeuticsHoldingsInc, inva:CommonStockAndWarrants


Securities
Period End2020-08-272020-04-12
Value1235
Percentage of SecuritiesPurchaseAgreementAmount0.00.0

inva:SecuritiesPurchaseAgreementPurchasePrice us-gaap:ConsolidatedEntities, us-gaap:StatementScenario, us-gaap:FinancialInstrument, us-gaap:SubsequentEventType

inva:SecuritiesPurchaseAgreementPurchasePrice

inva:ArmataPharmaceuticalsInc, inva:SecuritiesPurchaseAgreementTrancheOne, inva:CommonStockAndWarrants, us-gaap:SubsequentEvent


Securities
Period End2021-01-26
Value6.1
Percentage of SecuritiesPurchaseAgreementPurchasePrice100.0

inva:ArmataPharmaceuticalsInc, inva:SecuritiesPurchaseAgreementTrancheTwo, inva:CommonStockAndWarrants, us-gaap:SubsequentEvent


Securities
Period End2021-03-31
Value13
Percentage of SecuritiesPurchaseAgreementPurchasePrice0.0

inva:VotingAgreementMaximumVotingRightsPercent us-gaap:ConsolidatedEntities

inva:VotingAgreementMaximumVotingRightsPercent

inva:ArmataPharmaceuticalsInc


Voting
Period End2021-03-31
Value49.5
Percentage of VotingAgreementMaximumVotingRightsPercent100.0

us-gaap:AmortizationOfDebtDiscountPremium us-gaap:DebtInstrument, us-gaap:LongtermDebtType

us-gaap:AmortizationOfDebtDiscountPremium

inva:Percent2.50ConvertibleDebt, inva:SeniorUnsecuredConvertibleNotes


Amortization
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value1911000.01867000.01828000.01786000.01749000.01709000.01673000.01635000.01601000.01564000.01532000.01496000.01479000.01434000.0834000.0
Percentage of AmortizationOfDebtDiscountPremium100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AmortizationOfFinancingCostsAndDiscounts

us-gaap:AmortizationOfFinancingCostsAndDiscounts


Amortization
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312013-12-31
Value2211000.02167000.02120000.02078000.02032000.02010000.01969000.01931000.01889000.01853000.01867000.01936000.02092000.02163000.01552000.0714000.0687000.0709000.0724000.0715000.0699000.0647000.0769000.0763000.0764000.0858000.0159000.0
Percentage of AmortizationOfFinancingCostsAndDiscounts100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CapitalizedContractCostAmortization us-gaap:ProductOrService, us-gaap:RelatedPartyTransactionsByRelatedParty

us-gaap:CapitalizedContractCostAmortization

us-gaap:Royalty, inva:GSK


Capitalized
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-30
Value3.4563.4553.4563.4563.4563.4553.4563.4563.4563.4553.4563.4563.4553.456
Percentage of CapitalizedContractCostAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate


Effective
Period End2021-03-31
Value21.0
Percentage of EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate100.0

us-gaap:EquitySecuritiesFvNiUnrealizedLoss us-gaap:ConsolidatedEntities

us-gaap:EquitySecuritiesFvNiUnrealizedLoss

inva:EntasisTherapeuticsHoldingsInc


Equity
Period End2021-03-31
Value11
Percentage of EquitySecuritiesFvNiUnrealizedLoss100.0

us-gaap:EquitySecuritiesFvNiUnrealizedLoss us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

inva:Incarda, inva:SeriesCPreferredStockAndWarrants


Equity
Period End2021-03-31
Value0.5
Percentage of EquitySecuritiesFvNiUnrealizedLoss4.3

us-gaap:IncreaseDecreaseInAccruedLiabilities

us-gaap:IncreaseDecreaseInAccruedLiabilities


Increase
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value227000.0552000.0267000.0111000.0-126000.0-546000.0-236000.0177000.0166000.0-982000.0844000.0163000.0-1702000.0525000.0-848000.0-510000.0752000.056000.0847000.0-2000.0-625000.0126000.0858000.0-193000.0-1516000.0-562000.0-1803000.0-2574000.04448000.01378000.01531000.06117000.0-3176000.02073000.02054000.0701000.0-6657000.05803000.02809000.02543000.0-6031000.0
Percentage of IncreaseDecreaseInAccruedLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInDeferredLeasingFees

us-gaap:IncreaseDecreaseInDeferredLeasingFees


Increase
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-312017-12-31
Value270000.0-270000.054000.081000.082000.081000.081000.081000.082000.081000.082000.0
Percentage of IncreaseDecreaseInDeferredLeasingFees100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent

us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent


Increase
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302015-03-31
Value-4.9571.7819.7480.2682.707101.6488.924-24.64718-5.40614-14.70518-9.91818-3.12100.8048.2781.3113.758-0.311
Percentage of IncreaseDecreaseInDueFromRelatedPartiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInInterestPayableNet

us-gaap:IncreaseDecreaseInInterestPayableNet


Increase
Period End2021-03-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
Value-2.484-2.4842.484-2.4842.379-2.4892.487-2.4892.489-3.342.57-3.3752.354-3.5370.703-1.4281.222-1.2171.261-1.3491.521-1.5351.73-1.356-11.916
Percentage of IncreaseDecreaseInInterestPayableNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets


Increase
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value-571000.0942000.053000.0-177000.0-140000.0579000.0-76000.0-243000.0-147000.0336000.0-63000.0-374000.0196000.0315000.0-203000.0-238000.0114000.0232000.0-204000.0-237000.0161000.0199000.0-82000.0-316000.0-121000.0286000.0-125000.0-1955000.02132000.0-71000.0392000.0-1581000.01224000.0194000.0374000.0-502000.0375000.0-305000.0-266000.0-1644000.0-73000.0
Percentage of IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities

us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities


Incremental
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-03-31
Value120.01212120.01212120.01212120.012121212120.0
Percentage of IncrementalCommonSharesAttributableToConversionOfDebtSecurities100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.00.0100.0100.0100.0100.0100.00.0

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements


Incremental
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-03-31
Value70000.0-3000.025000.032000.085000.0-1000.035000.051000.0128000.0-79000.0238000.0337000.0773000.037000.0766000.0660000.0660000.0-43000.0313000.0696000.0
Percentage of IncrementalCommonSharesAttributableToShareBasedPaymentArrangements100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InterestExpenseDebtExcludingAmortization us-gaap:DebtInstrument, us-gaap:LongtermDebtType

us-gaap:InterestExpenseDebtExcludingAmortization

inva:Percent2.50ConvertibleDebt, inva:SeniorUnsecuredConvertibleNotes


Interest
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value1203000.01204000.01203000.01203000.01203000.01204000.01203000.01203000.01203000.01203000.01203000.01203000.01190000.01203000.0722000.0
Percentage of InterestExpenseDebtExcludingAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InterestOnConvertibleDebtNetOfTax

us-gaap:InterestOnConvertibleDebtNetOfTax


Interest
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-30
Value1204000.01182000.01171000.01184000.01180000.01166000.01157000.01158000.01415000.01419000.01413000.01417000.01412000.01416000.01410000.01414000.01407000.05790000.01429000.01457000.000
Percentage of InterestOnConvertibleDebtNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0

us-gaap:InvestmentIncomeInvestmentExpense us-gaap:ConsolidatedEntities

us-gaap:InvestmentIncomeInvestmentExpense

inva:IspFundLp


Investment
Period End2021-03-31
Value400000.0
Percentage of InvestmentIncomeInvestmentExpense100.0

us-gaap:InvestmentIncomeNet

us-gaap:InvestmentIncomeNet


Investment
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-30
Value30000.023000.041000.0158000.01302000.01538000.01624000.01403000.0975000.0519000.0370000.0380000.0391000.0393000.0376000.0306000.0236000.0171000.0162000.0157000.092000.052000.090000.085000.0116000.0117000.093000.0165000.0188000.0211000.0192000.0190000.0185000.0156000.0158000.0
Percentage of InvestmentIncomeNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium

us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium


Investment
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-06-302016-03-31
Value07000.064000.0272000.0490000.0615000.0768000.0356000.032000.064000.060000.0100000.099000.012000.011000.0-17000.0-17000.03000.0
Percentage of InvestmentIncomeNetAmortizationOfDiscountAndPremium0.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance

us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance


Noncontrolling
Period End2021-03-312020-09-302020-06-30
Value8000.08000.0350000.0
Percentage of NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance100.0100.0100.0

us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Noncontrolling
Period End2021-03-312020-09-302020-06-30
Value8000.08000.0350000.0
Percentage of NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent


Other
Period End2020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value2000.0-35000.06000.0-8000.023000.013000.0-4000.0
Percentage of OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Other
Period End2020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value2000.0-35000.06000.0-8000.023000.013000.0-4000.0
Percentage of OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax


Other
Period End2020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value2000.0-35000.06000.02000.0-8000.023000.013000.007000.012000.0-4000.0-15000.0-3000.01000.0-2000.0-8000.02000.08000.01000.03000.021000.02000.01226000.0110000.0-3903000.0-107000.0-17000.0225000.0-100000.0-25000.0-41000.0-17000.0-36000.0-5000.0
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherNoncashIncomeExpense

us-gaap:OtherNoncashIncomeExpense


Other
Period End2021-03-312020-12-312020-09-302015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
Value-8000.0-7000.0-8000.01000.000002000.00-20000.02000.01000.0
Percentage of OtherNoncashIncomeExpense100.0100.0100.0100.00.00.00.00.0100.00.0100.0100.0100.0

us-gaap:PaymentsOfStockIssuanceCosts us-gaap:ConsolidatedEntities

us-gaap:PaymentsOfStockIssuanceCosts

inva:Imaginab


Payments
Period End2021-03-18
Value400000.0
Percentage of PaymentsOfStockIssuanceCosts100.0

us-gaap:PaymentsOfStockIssuanceCosts us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

inva:Incarda, inva:SeriesCPreferredStockAndWarrants


Payments
Period End2020-10-31
Value800000.0
Percentage of PaymentsOfStockIssuanceCosts0.0

us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation

us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation


Payments
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302015-03-31
Value25000.09000.011000.017000.055000.08000.07000.09000.065000.0-9000.0242000.0229000.02611000.0945000.0336000.0294000.0553000.0195000.0287000.0155000.0442000.01460000.0661000.0
Percentage of PaymentsRelatedToTaxWithholdingForShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsToAcquireLongtermInvestments

us-gaap:PaymentsToAcquireLongtermInvestments


Payments
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-06-302019-03-31
Value263151235250.00.0
Percentage of PaymentsToAcquireLongtermInvestments100.0100.0100.0100.0100.00.00.0

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:PaymentsToAcquireMarketableSecurities


Payments
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312012-03-312011-06-302011-03-31
Value0.00.00.0120.9931189.893102359976
Percentage of PaymentsToAcquireMarketableSecurities0.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsToMinorityShareholders

us-gaap:PaymentsToMinorityShareholders


Payments
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-31
Value212.5120.012150.0100.00.03.0671.9890.8090.090.00.00.0
Percentage of PaymentsToMinorityShareholders100.0100.00.0100.0100.00.0100.00.00.0100.0100.0100.0100.00.00.00.0

us-gaap:ProceedsFromIssuanceOfCommonStock

us-gaap:ProceedsFromIssuanceOfCommonStock


Proceeds
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value0.015-0.0010.1970.2250.0090.0890.210.3190.6850.00.340.1140.2470.0030.1770.0080.0440.0060.1620.1730.0521.3642.8851.74713115.5141813113232.9917.161122142.5322.8911.369.82411
Percentage of ProceedsFromIssuanceOfCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities


Proceeds
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312012-03-312011-06-302011-03-31
Value0.04.02854521033027454871
Percentage of ProceedsFromSaleAndMaturityOfMarketableSecurities0.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate us-gaap:Range, us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

srt:WeightedAverage, us-gaap:EmployeeStockOption


Share
Period End2021-03-31
Value0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate0.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate us-gaap:Range, us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

srt:WeightedAverage, us-gaap:EmployeeStockOption


Share
Period End2021-03-31
Value1.1
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate us-gaap:Range, us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

srt:WeightedAverage, us-gaap:EmployeeStockOption


Share
Period End2021-03-31
Value45.6
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:Range, us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

srt:WeightedAverage, us-gaap:EmployeeStockOption


Share
Period End2021-03-31
Value5.42
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue100.0

us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation us-gaap:StatementEquityComponents

us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation

us-gaap:CommonStock


Stock
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value16000.0-1000.072000.032000.07000.089000.085000.0-571000.0
Percentage of StockIssuedDuringPeriodSharesShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation


Stock
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value-0.025-0.0120.180.170.0820.2010.254-2.497
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Stock
Period End2021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-03-31
Value-0.025-0.0110.1780.170.0820.20.253-2.492
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.091.798.9100.0100.099.599.699.8

us-gaap:CommonStock


Stock
Period End2020-09-302020-06-302020-03-312019-06-302019-03-312018-03-31
Value-0.0010.0020.00.0010.001-0.005
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation8.31.10.00.50.40.2

us-gaap:UnrealizedGainLossOnInvestments

us-gaap:UnrealizedGainLossOnInvestments


Unrealized
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-06-302019-03-31
Value5411-29.36846210.00.0
Percentage of UnrealizedGainLossOnInvestments100.0100.0100.0100.0100.00.00.0

us-gaap:UnrealizedGainLossOnInvestments us-gaap:ConsolidatedEntities

inva:IspFundLp


Unrealized
Period End2021-03-31
Value5.8
Percentage of UnrealizedGainLossOnInvestments10.6

us-gaap:WeightedAverageNumberOfSharesIssuedBasic

us-gaap:WeightedAverageNumberOfSharesIssuedBasic


Weighted
Period End2020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-06-302015-03-312014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
Value1011011010.0161011011010.043100100100-0.291106107107-0.8481091111121151141131122.05109100991.5769791860.255848483
Percentage of WeightedAverageNumberOfSharesIssuedBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseAfterYearFive

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseAfterYearFive


Capitalized
Period End2020-12-31
Value56
Percentage of CapitalizedFeesPaidToRelatedPartyAmortizationExpenseAfterYearFive100.0

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseNextTwelveMonths

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseNextTwelveMonths


Capitalized
Period End2020-12-31
Value13
Percentage of CapitalizedFeesPaidToRelatedPartyAmortizationExpenseNextTwelveMonths100.0

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFive

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFive


Capitalized
Period End2020-12-31
Value13
Percentage of CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFive100.0

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFour

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFour


Capitalized
Period End2020-12-31
Value13
Percentage of CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFour100.0

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearThree

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearThree


Capitalized
Period End2020-12-31
Value13
Percentage of CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearThree100.0

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearTwo

inva:CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearTwo


Capitalized
Period End2020-12-31
Value13
Percentage of CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearTwo100.0

inva:ConvertibleSeniorDebtFairValueDisclosures us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

inva:ConvertibleSeniorDebtFairValueDisclosures

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsNonrecurring, us-gaap:Debt


Convertible
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value203206191198191208205230
Percentage of ConvertibleSeniorDebtFairValueDisclosures100.0100.0100.0100.0100.0100.0100.0100.0

inva:ConvertibleSeniorDebtFairValueDisclosures us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsNonrecurring, us-gaap:Debt


Convertible
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value203206191198191208205230
Percentage of ConvertibleSeniorDebtFairValueDisclosures100.0100.0100.0100.0100.0100.0100.0100.0

inva:ConvertibleSubordinatedDebtFairValueDisclosures us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

inva:ConvertibleSubordinatedDebtFairValueDisclosures

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsNonrecurring, us-gaap:Debt


Convertible
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value242239230246216243245258
Percentage of ConvertibleSubordinatedDebtFairValueDisclosures100.0100.0100.0100.0100.0100.0100.0100.0

inva:ConvertibleSubordinatedDebtFairValueDisclosures us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsNonrecurring, us-gaap:Debt


Convertible
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value242239230246216243245258
Percentage of ConvertibleSubordinatedDebtFairValueDisclosures100.0100.0100.0100.0100.0100.0100.0100.0

inva:EquitySecuritiesFvNiNonCurrent

inva:EquitySecuritiesFvNiNonCurrent


Equity
Period End2020-09-302020-06-302020-03-312019-12-31
Value111128460.0
Percentage of EquitySecuritiesFvNiNonCurrent100.0100.0100.00.0

inva:LongTermDebtMaturityAfterYearFour

inva:LongTermDebtMaturityAfterYearFour


Long
Period End2020-09-30
Value192
Percentage of LongTermDebtMaturityAfterYearFour100.0

inva:OperatingLossCarryforwardsIndefinitePeriod us-gaap:IncomeTaxAuthority

inva:OperatingLossCarryforwardsIndefinitePeriod

us-gaap:DomesticCountry


Operating
Period End2020-12-31
Value2000000.0
Percentage of OperatingLossCarryforwardsIndefinitePeriod100.0

inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty us-gaap:RelatedPartyTransactionsByRelatedParty

inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty

inva:GSK


Related
Period End2020-12-312017-12-312016-12-31
Value31.60.3140.295
Percentage of RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty100.0100.0100.0

inva:SarissaCapitalManagementLp


Related
Period End2020-12-31
Value6.3
Percentage of RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty19.9

inva:SecuritiesPurchaseAgreementNumberOfSharesPurchased us-gaap:ConsolidatedEntities, us-gaap:StatementScenario, us-gaap:FinancialInstrument, us-gaap:SubsequentEventType

inva:SecuritiesPurchaseAgreementNumberOfSharesPurchased

inva:ArmataPharmaceuticalsInc, inva:SecuritiesPurchaseAgreementTrancheOne, inva:CommonStockAndWarrants, us-gaap:SubsequentEvent


Securities
Period End2021-01-26
Value1900000.0
Percentage of SecuritiesPurchaseAgreementNumberOfSharesPurchased100.0

inva:ArmataPharmaceuticalsInc, inva:SecuritiesPurchaseAgreementTrancheTwo, inva:CommonStockAndWarrants, us-gaap:SubsequentEvent


Securities
Period End2021-03-31
Value4300000.0
Percentage of SecuritiesPurchaseAgreementNumberOfSharesPurchased0.0

us-gaap:AssetsFairValueDisclosure us-gaap:ConsolidatedEntities, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType

us-gaap:AssetsFairValueDisclosure

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value7125
Percentage of AssetsFairValueDisclosure100.0100.0

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value5418
Percentage of AssetsFairValueDisclosure76.269.5

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value3946
Percentage of AssetsFairValueDisclosure56.2177.7

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value2631
Percentage of AssetsFairValueDisclosure37.4122.8

inva:Incarda, us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value0.6641.147
Percentage of AssetsFairValueDisclosure0.94.4

us-gaap:AssetsFairValueDisclosure us-gaap:ConsolidatedEntities, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value7125
Percentage of AssetsFairValueDisclosure100.0100.0

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value5418
Percentage of AssetsFairValueDisclosure76.269.5

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value3946
Percentage of AssetsFairValueDisclosure56.2177.7

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value2631
Percentage of AssetsFairValueDisclosure37.4122.8

inva:Incarda, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value0.6641.147
Percentage of AssetsFairValueDisclosure0.94.4

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-302020-03-31
Value273427
Percentage of AssetsFairValueDisclosure0.00.00.0

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-302020-03-31
Value202619
Percentage of AssetsFairValueDisclosure0.00.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-30
Value3841
Percentage of AssetsFairValueDisclosure0.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-30
Value2526
Percentage of AssetsFairValueDisclosure0.00.0

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType

inva:IspFundLp, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, inva:EquityInvestmentsAndMoneyMarketFunds


Assets
Period End2021-03-312020-12-31
Value304299
Percentage of AssetsFairValueDisclosure428.81153.0

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

inva:IspFundLp, us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Assets
Period End2021-03-312020-12-31
Value174284
Percentage of AssetsFairValueDisclosure245.21097.2

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument, us-gaap:InvestmentType

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-302020-03-31
Value273427
Percentage of AssetsFairValueDisclosure0.00.00.0

inva:ArmataPharmaceuticalsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-302020-03-31
Value202619
Percentage of AssetsFairValueDisclosure0.00.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommonStock, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-30
Value3841
Percentage of AssetsFairValueDisclosure0.00.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:FairValueMeasurementsRecurring, us-gaap:Warrant, us-gaap:EquitySecurities


Assets
Period End2020-09-302020-06-30
Value2526
Percentage of AssetsFairValueDisclosure0.00.0

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType

inva:IspFundLp, us-gaap:FairValueMeasurementsRecurring, inva:EquityInvestmentsAndMoneyMarketFunds


Assets
Period End2021-03-312020-12-31
Value304299
Percentage of AssetsFairValueDisclosure428.81153.0

inva:IspFundLp, us-gaap:FairValueMeasurementsRecurring, us-gaap:EquitySecurities


Assets
Period End2021-03-312020-12-31
Value13014
Percentage of AssetsFairValueDisclosure183.755.9

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:FinancialInstrument

inva:IspFundLp, us-gaap:MoneyMarketFunds


Assets
Period End2020-12-31
Value284
Percentage of AssetsFairValueDisclosure1097.2

us-gaap:AssetsFairValueDisclosure us-gaap:CounterpartyName, us-gaap:InvestmentType

inva:IspFundLp, us-gaap:EquitySecurities


Assets
Period End2020-12-31
Value14
Percentage of AssetsFairValueDisclosure55.9

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-31
Value6645764964543122334549388117611189964148
Percentage of AssetsFairValueDisclosure935.42219.60.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-31
Value804945578272135591120346044688428
Percentage of AssetsFairValueDisclosure113.6192.40.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-03-312020-12-312020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-31
Value0.6641.1470.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of AssetsFairValueDisclosure0.94.40.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value248204430378285233454938811761
Percentage of AssetsFairValueDisclosure350.3789.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-31
Value7466275415113953061801085010151122162168148176
Percentage of AssetsFairValueDisclosure1050.02416.40.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Assets
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value248204430378285233454938811761
Percentage of AssetsFairValueDisclosure350.3789.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis


Available
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value2482044303823483061801085010151122
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis us-gaap:FinancialInstrument

us-gaap:MoneyMarketFunds


Available
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value248204430378285233454938811761
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis100.0100.0100.099.081.976.325.145.376.580.033.350.5

us-gaap:AvailableForSaleSecuritiesDebtSecurities

us-gaap:AvailableForSaleSecuritiesDebtSecurities


Available
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value2482044303823483061801085010151122
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleSecuritiesDebtSecurities us-gaap:FinancialInstrument

us-gaap:MoneyMarketFunds


Available
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value248204430378285233454938811761
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.099.081.976.325.145.376.580.033.350.5

us-gaap:CapitalizedContractCostAccumulatedAmortization us-gaap:RelatedPartyTransactionsByRelatedParty

us-gaap:CapitalizedContractCostAccumulatedAmortization

inva:GSK


Capitalized
Period End2020-12-312019-12-312018-12-312017-12-31
Value94806753
Percentage of CapitalizedContractCostAccumulatedAmortization100.0100.0100.0100.0

us-gaap:CapitalizedContractCostNet

us-gaap:CapitalizedContractCostNet


Capitalized
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302017-12-31
Value121125128132135139149152156166
Percentage of CapitalizedContractCostNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CapitalizedContractCostNet us-gaap:RelatedPartyTransactionsByRelatedParty

inva:GSK


Capitalized
Period End2020-12-312019-12-312018-12-312017-12-31
Value125139152166
Percentage of CapitalizedContractCostNet100.0100.0100.0100.0

us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 us-gaap:ConsolidatedEntities, us-gaap:FinancialInstrument

us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

inva:ArmataPharmaceuticalsInc, inva:WarrantsPurchasedIn2021


Class
Period End2021-03-31
Value3.25
Percentage of ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1100.0

inva:ArmataPharmaceuticalsInc, us-gaap:Warrant


Class
Period End2020-12-31
Value2.87
Percentage of ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights10.0

inva:EntasisTherapeuticsHoldingsInc, inva:WarrantsAcquiredInThirdQuarterOf2020


Class
Period End2020-09-30
Value2.675
Percentage of ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights10.0

inva:EntasisTherapeuticsHoldingsInc, us-gaap:Warrant


Class
Period End2020-08-272020-04-12
Value2.6752.5
Percentage of ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights10.00.0

us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 us-gaap:CounterpartyName, us-gaap:FinancialInstrument

inva:EntasisTherapeuticsHoldingsInc, us-gaap:Warrant


Class
Period End2020-08-272020-04-12
Value2.6752.5
Percentage of ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights10.00.0

us-gaap:DebtInstrumentCarryingAmount

us-gaap:DebtInstrumentCarryingAmount


Debt
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-31
Value433433433433433433447447447557557677683720728748
Percentage of DebtInstrumentCarryingAmount100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DebtInstrumentCarryingAmount us-gaap:DebtInstrument, us-gaap:LongtermDebtType

inva:Percent2.125ConvertibleDebt, us-gaap:ConvertibleSubordinatedDebt


Debt
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302017-12-312014-12-31
Value240240240240240240240240240240240241
Percentage of DebtInstrumentCarryingAmount55.655.655.655.655.655.653.953.953.943.235.60.0

us-gaap:DebtInstrumentFairValue us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:DebtInstrumentFairValue

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsNonrecurring, us-gaap:Debt


Debt
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value445445421445408452465503
Percentage of DebtInstrumentFairValue100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DebtInstrumentFairValue us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsNonrecurring, us-gaap:Debt


Debt
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value445445421445408452465503
Percentage of DebtInstrumentFairValue100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet

us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet


Debt
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-31
Value4547505254566264667072778012
Percentage of DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet us-gaap:DebtInstrument, us-gaap:LongtermDebtType

inva:Percent2.50ConvertibleDebt, inva:SeniorUnsecuredConvertibleNotes


Debt
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value44464850525460616365666869
Percentage of DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet97.797.597.397.297.096.996.195.995.892.191.987.887.3

us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss


Debt
Period End2021-03-31
Value0
Percentage of DebtSecuritiesAvailableForSaleAllowanceForCreditLoss0.0

us-gaap:DeferredIncomeTaxAssetsNet

us-gaap:DeferredIncomeTaxAssetsNet


Deferred
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-31
Value7493109118138154187196
Percentage of DeferredIncomeTaxAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsGross


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-30
Value1782292733174844634595910.00.05210.00.0
Percentage of DeferredTaxAssetsGross100.0100.0100.0100.0100.0100.0100.0100.00.00.0100.00.00.0

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Value121172215257417392386479411359
Percentage of DeferredTaxAssetsOperatingLossCarryforwards100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsOther


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Value1.11.4121.6473.0131718323331
Percentage of DeferredTaxAssetsOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch

us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value5555565753
Percentage of DeferredTaxAssetsTaxCreditCarryforwardsResearch100.0100.0100.0100.0100.0

us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts

us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value101113140.0
Percentage of DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts100.0100.0100.0100.00.0

us-gaap:DeferredTaxLiabilitiesInvestments

us-gaap:DeferredTaxLiabilitiesInvestments


Deferred
Period End2020-12-31
Value10
Percentage of DeferredTaxLiabilitiesInvestments100.0

us-gaap:DueFromRelatedPartiesCurrent

us-gaap:DueFromRelatedPartiesCurrent


Due
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value88939282827958836570557051434626104.0123.4730.7752.2470.5170.3370.1230.0710.0940.0630.2230.0320.194
Percentage of DueFromRelatedPartiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DueFromRelatedPartiesCurrent us-gaap:ConsolidatedEntities

inva:TheravanceRespiratoryCompanyLlc


Due
Period End2021-03-312020-12-312020-09-302020-06-302019-12-31
Value2224162514
Percentage of DueFromRelatedPartiesCurrent24.826.617.831.118.1

us-gaap:EmployeeRelatedLiabilitiesCurrent

us-gaap:EmployeeRelatedLiabilitiesCurrent


Employee
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value0.6520.490.3840.2910.2740.6470.3250.471.550.6950.5371.7211.6470.9982.3611.1260.9131.6591.3921.9591.2031.02313108.3626.0019.0027.7145.6694.8849.6435.1548.617
Percentage of EmployeeRelatedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized


Employee
Period End2020-12-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value2.0481.3181.6441.4431.9167.7568.3151113171111105643
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized us-gaap:AwardType

us-gaap:EmployeeStockOption


Employee
Period End2020-12-312018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-30
Value1.3280.0190.1570.3050.4550.750.8991.21.41.5311.73.2073.52.219168.76.96.4426.56.8
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized64.80.21.92.63.34.27.50.00.013.60.029.70.00.00.030.00.00.014.60.00.0

us-gaap:RestrictedStock


Employee
Period End2020-12-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-30
Value0.3690.9421.3170.7610.8723.5214.0687.7648.887118.0768.2759.15.1473.61921232528232527
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized18.071.580.152.745.545.448.965.964.564.767.873.50.047.70.00.00.041.40.00.053.50.00.0

us-gaap:RestrictedStockUnitsRSU


Employee
Period End2020-12-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-30
Value0.3510.3760.3270.6821.0442.0961.6571.4871.6231.4881.5392.01.51.4462.11.8141.51.812151820141619
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized17.128.519.947.354.527.019.912.611.88.312.90.00.012.80.016.80.00.00.027.50.00.031.90.00.0

us-gaap:EquityMethodInvestmentOwnershipPercentage us-gaap:ConsolidatedEntities

us-gaap:EquityMethodInvestmentOwnershipPercentage

inva:ArmataPharmaceuticalsInc


Equity
Period End2021-03-312020-12-31
Value59.646.6
Percentage of EquityMethodInvestmentOwnershipPercentage100.0100.0

inva:Imaginab


Equity
Period End2021-03-31
Value13.0
Percentage of EquityMethodInvestmentOwnershipPercentage21.8

inva:Incarda


Equity
Period End2021-03-312020-12-31
Value13.013.4
Percentage of EquityMethodInvestmentOwnershipPercentage21.828.8

us-gaap:EquityMethodInvestmentOwnershipPercentage us-gaap:CounterpartyName

inva:ArmataPharmaceuticalsInc


Equity
Period End2020-09-302020-06-302020-03-31
Value46.70.4670.467
Percentage of EquityMethodInvestmentOwnershipPercentage0.00.00.0

inva:EntasisTherapeuticsHoldingsInc


Equity
Period End2020-09-012020-06-112020-04-12
Value52.651.30.513
Percentage of EquityMethodInvestmentOwnershipPercentage0.00.00.0

us-gaap:InterestPayableCurrent

us-gaap:InterestPayableCurrent


Interest
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-312016-06-302016-03-312015-12-312015-09-302014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302012-12-312012-09-302012-06-302012-03-312011-12-312011-06-302010-12-31
Value1.6684.1521.6684.1521.6684.1521.7754.2641.7755.1152.5455.923.5666.47.8287.8236.5627.9116.397.55119111.2732.81.2734.9122.3721.0782.3721.0782.3722.3722.372
Percentage of InterestPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths


Lessee
Period End2021-03-312020-09-30
Value109000.0123000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths100.0100.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths us-gaap:StatementGeographical

inva:BurlingameCalifornia


Lessee
Period End2020-12-31
Value123000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths0.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear


Lessee
Period End2021-03-312020-09-30
Value92000.030000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear100.0100.0

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive


Long
Period End2020-12-31
Value192
Percentage of LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive100.0

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour


Long
Period End2021-03-312020-12-31
Value192240
Percentage of LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour100.0100.0

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree


Long
Period End2020-09-30
Value240
Percentage of LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree100.0

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo


Long
Period End2021-03-31
Value240
Percentage of LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo100.0

us-gaap:MembersEquity us-gaap:ConsolidatedEntities

us-gaap:MembersEquity

inva:TheravanceRespiratoryCompanyLlc


Members
Period End2021-03-312020-12-31
Value7279
Percentage of MembersEquity100.0100.0

us-gaap:OperatingLossCarryforwards us-gaap:IncomeTaxAuthority

us-gaap:OperatingLossCarryforwards

us-gaap:DomesticCountry


Operating
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Value40060080010001.111741158
Percentage of OperatingLossCarryforwards100.0100.0100.0100.0100.0100.0100.0

us-gaap:StateAndLocalJurisdiction


Operating
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value6506496536546746761008890563
Percentage of OperatingLossCarryforwards162.7108.281.665.461300.057.687.10.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

us-gaap:RestrictedStock


Share
Period End2020-12-312019-12-31
Value14.6114.46
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue100.0100.0

us-gaap:RestrictedStockUnitsRSU


Share
Period End2020-12-312019-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value13.313.9418.3418.5321.5317.3215.4712.4514.15
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue91.096.40.00.00.00.00.00.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate

inva:EmployeeStockPurchasePlan


Share
Period End2020-12-31
Value15.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

us-gaap:RestrictedStock


Share
Period End2020-12-312019-12-31
Value30000.078000.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber100.0100.0

us-gaap:RestrictedStockUnitsRSU


Share
Period End2020-12-312019-12-31
Value85000.094000.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber283.3120.5

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 us-gaap:AwardType

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

us-gaap:EmployeeStockOption


Sharebased
Period End2020-12-31
Value0
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue10.0

us-gaap:TaxCreditCarryforwardAmount us-gaap:IncomeTaxAuthority

us-gaap:TaxCreditCarryforwardAmount

us-gaap:DomesticCountry


Tax
Period End2020-12-312019-12-31
Value4344
Percentage of TaxCreditCarryforwardAmount100.0100.0

us-gaap:TaxCreditCarryforwardAmount us-gaap:IncomeTaxAuthority, us-gaap:TaxCreditCarryforward

us-gaap:StateAndLocalJurisdiction, us-gaap:Research


Tax
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value323232323232325752
Percentage of TaxCreditCarryforwardAmount73.972.70.00.00.00.00.00.00.0

us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate


Unrecognized
Period End2020-12-31
Value8000000.0
Percentage of UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate100.0

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:GainLossOnInvestments
us-gaap:CounterpartyName
(None,)
Gain Loss On Investmentsus-gaap: Counterparty Name
us-gaap:OperatingExpenses
us-gaap:ConsolidatedEntities
(None,)
Operating Expensesus-gaap: Consolidated Entities
us-gaap:ProfitLoss
us-gaap:StatementEquityComponents
(None,)
Profit Lossus-gaap: Statement Equity Components
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:Assets
us-gaap:ConsolidatedEntities
(None,)
Assetsus-gaap: Consolidated Entities
us-gaap:CashAndCashEquivalentsAtCarryingValue
us-gaap:ConsolidatedEntities
(None,)
Cash And Cash Equivalents At Carrying Valueus-gaap: Consolidated Entities
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)
Stockholders Equity Including Portion Attributable To Noncontrolling Interestus-gaap: Statement Equity Components
us-gaap:ProfitLoss
us-gaap:StatementEquityComponents
(None,)
Profit Lossus-gaap: Statement Equity Components